Method of targeting gene delivery using viral vectors

ABSTRACT

Methods and compositions are provided for delivering a polynucleotide encoding a gene of interest to a target cell using a virus. The virus envelope comprises a cell-specific binding determinant that recognizes and binds to a component on the target cell surface, leading to endocytosis of the virus. A separate fusogenic molecule is also present on the envelope and facilitates delivery of the polynucleotide across the membrane and into the cytosol of the target cell. The methods and related compositions can be used for treating patients having suffering from a wide range of conditions, including infection, such as HIV; cancers, such as non-Hodgkin&#39;s lymphoma and breast cancer; and hematological disorders, such as severe combined immunodeficiency.

CROSS-REFERENCE TO RELATED APPLICATIONS

The present application claims priority under 35 U.S.C. § 120 as acontinuation of U.S. patent application Ser. No. 13/041,115, now U.S.Pat. No. 8,821,856, which claims priority under 35 U.S.C. § 120 as acontinuation of U.S. patent application Ser. No. 11/446,353, filed Jun.1, 2006, now abandoned, which claims priority under 35 U.S.C. § 119(e)to U.S. Provisional Application No. 60/686,215, filed Jun. 1, 2005 andU.S. Provisional Application No. 60/738,078, filed Nov. 19, 2005. All ofthe aforementioned priority applications are herein expresslyincorporated by reference in their entirety.

BACKGROUND OF THE INVENTION

1. Field of the Invention

The invention relates generally to targeted gene delivery, and moreparticularly to the use of a recombinant virus comprising a fusogenicmolecule and a distinct affinity molecule.

2. Description of the Related Art

The delivery of functional genes and other polynucleotides intoparticular target cells can be used in a variety of contexts. Forexample, gene therapy can be used to prevent or treat disease. Aparticularly desirable gene delivery protocol would be able to preciselydeliver a gene of interest to specific cells or organs in vivo. Certainviruses are naturally suited for gene delivery, and significant efforthas been focused on engineering viral vectors as gene transfer vehicles.Among these viruses, oncoretroviral and lentiviral vectors exhibitpromising features because they have the ability to produce stabletransduction, maintain long-term transgene expression and, forlentiviruses, enable transduction of non-dividing cells. Targeting suchviruses to particular cell types has proved to be challenging.

Many attempts have been made to develop targetable transduction systemsusing retroviral and lentiviral vectors (see, for example, D.Lavillette, S. J. Russell, F. L. Cosset, Curr. Opin. Biotech. 12, 461(2001), V. Sandrin, S. J. Russell, F. L. Cosset, Curr. Top. Microbio.Immunol. 281, 137 (2003)). Significant effort has been devoted toaltering the envelope glycoprotein (env), the protein that isresponsible for binding the virus to cell surface receptors and formediating entry. The plasticity of the surface domain of env allowsinsertion of ligands, peptides and single-chain antibodies, which candirect the vectors to specific cell types (N. V. Somia, M. Zoppe, I. M.Verma, Proc. Natl. Acad. Sci. USA 92, 7570 (1995)). However, thismanipulation adversely affects the fusion domain of env, resulting inlow viral titers. The unknown and delicate coupling mechanisms ofbinding and fusion make it extremely difficult to reconstitute fusionfunction once the surface domain of the same molecule has been altered.

Another approach involves complex env with a ligand protein or antibodyto form a bridge to attach the virus to specific cells (e.g., K.Morizono, G. Bristol, Y. M. Xie, S. K. P. Kung, I. S. Y. Chen, J. Virol.75, 8016 (2001). The challenge to this approach is that env, oncecomplexed with the one end of the bridge molecule, fuses inefficiently.Since no practical strategies are available for targeted in vivo genedelivery, current gene therapy clinical trails are generally based on invitro transduction of purified cells followed by infusion of themodified cells into the patient. This in vitro approach is an expensiveprocedure with significant safety challenges.

SUMMARY OF THE INVENTION

According to one aspect of the invention, methods are provided fordelivering a polynucleotide to a desired cell, comprising infecting atarget cell with a recombinant retrovirus. In other aspects, recombinantretrovirus and various vectors and constructs for producing therecombinant retrovirus are provided.

The envelope of the recombinant retrovirus preferably comprises afusogenic molecule and a cell-specific binding determinant. In someembodiments, the recombinant retrovirus preferably comprises the R andU5 sequences from a 5′ lentiviral long terminal repeat (LTR), aself-inactivating lentiviral 3′ LTR, a fusogenic molecule, and acell-specific binding determinant. In some embodiments, the recombinantretrovirus is produced from the FUGW construct.

The fusogenic molecule is preferably a viral glycoprotein and may be,for example, a class I or class II fusogen. In some embodiments of theinvention, the fusogenic molecule is pH sensitive. Preferably the pHsensitivity is such that the fusogen is able to mediate delivery of theviral core across the membrane in the endocytic compartment of a targetcell. In some embodiments, the fusogenic molecule may have a loweredaffinity for a cognate molecule, such as a receptor or antigen.

In some embodiments, the fusogenic molecule is hemagglutinin, preferablya mutant hemagglutinin. In other embodiments, the fusogenic molecule isSIN. In still other embodiments, the fusogenic molecule comprises aviral glycoprotein derived from one of the following viruses: Lassafever virus, tick-borne encephalitis virus, Dengue virus, Hepatitis Bvirus, Rabies virus, Semliki Forest virus, Ross River virus, Aura virus,Borna disease virus, Hantaan virus, and SARS-CoV virus.

In some embodiments of the invention, the cell-specific bindingdeterminant comprises a protein that is able to bind with specificity toa cell surface molecule present on a target cell. Preferably, thebinding is high-affinity binding and in some embodiments thedissociation constant may be in the range of 10⁻⁶ to 10⁻¹² M. However,in other embodiments lower or higher affinity binding is possible.

The cell-specific binding determinant is preferably a protein, and insome embodiments is an antibody. The cell-specific binding determinantmay comprise more than one molecule. For example, if the cell-specificbinding determinant comprises an antibody, it may also compriseimmunoglobulin alpha and immunoglobulin beta. If the antibody is, forexample, a single chain antibody, it may be fused with a transmembranedomain from another protein. In some particular embodiments of theinvention, the antibody is a CD20 antibody, a CD34 antibody or anantibody against DEC-205.

In some embodiments of the invention, the 5′ LTR sequences are from HIV.The self-inactivating 3′ LTR may comprise a U3 element with a deletionof its enhancer sequence. The self-inactivating 3′ LTR may be a modifiedHIV 3′ LTR. The recombinant retrovirus may comprise other elements, suchas the woodchuck hepatitis virus enhancer element sequence and/or a tRNAamber suppressor sequence.

The recombinant retrovirus may be pseudotyped, for example, with thevesicular stomatitits virus envelope glycoprotein or ecotropic envelopeprotein 4.17.

In preferred embodiments, the recombinant retrovirus further comprisesone or more genes of interest to be delivered to the target cell. Thegene of interest is not limited in any way, and may, for example, encodea protein to be expressed in the cell. In other embodiments the gene ofinterest encodes an siRNA or other molecule to be expressed in the cell.In some embodiments at least one of the genes of interest is a reportergene, such as a fluorescent protein. In some embodiments, thefluorescent protein is green fluorescent protein.

The gene of interest is preferably linked to a promoter, such as an RNAPolymerase II or a Polymerase III promoter. In some embodiments, thepromoter is a ubiquitous promoter. For example, the ubiquitous promotermay be selected from the group consisting of the ubiquitin promoter, theCMV β-actin promoter and the pgk promoter. In other embodiments thepromoter may be a tissue specific promoter. A tissue specific promoter,if present, may, for example, be selected from the group consisting ofthe lck promoter, the myogenin promoter and the thy1 promoter.

The recombinant retrovirus may additionally comprise an enhanceroperably linked to the promoter. In some embodiments, the enhancer andpromoter are both CMV sequences.

In some embodiments of the invention, a packaging cell line istransfected with one or more vectors encoding the retroviral elements,the gene of interest, the fusogenic molecule and the cell-specificbinding determinant. Recombinant retrovirus is collected from thepackaging cell line and used to infect target cells, thereby deliveringthe gene of interest to the target cells. In some embodiments of theinvention, the packaging cell line is a 293 cell line.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a schematic representation of the generation of recombinantvirus bearing a cell-specific binding determinant and a fusogenicmolecule according to some embodiments of the invention.

FIG. 2 illustrates a molecular mechanism of targeted transduction of aviral particle that includes a fusogenic molecule and an affinitymolecule.

FIG. 3A illustrates the fusion protein HAmu derived from influenza A(FPV) hemagglutinin (HA). HA contains two glycoproteins aftermaturation: HAI_(—) for binding to cell surface receptor, sialic acid;and HA2 for triggering membrane fusion. Three point mutations within thereceptor binding sites (a1: Y106F, a2: E199Q, a3: G237K) were introducedto generate a binding-defective but fusion-competent fusogenic molecule(HAmu).

FIG. 3B illustrates a FACS analysis of virus-producing cells. 293T cellsthat were transiently transfected with separate plasmids encoding thefollowing: the lentiviral vector FUGW; the membrane-bound antibodyαCD20; the accessory proteins Igα and Igβ; the fusion protein HAmu; andviral gag, pol, and rev genes. Expression of αCD20 and HAmu was detectedusing anti-human IgG antibody and anti-FPV HA antibody.

FIG. 3C illustrates the fusion protein SINmu derived from Sindbis viralglycoprotein (SIN). SIN contains two membrane glycoproteins (E1 and E2)and a signal peptide (E3): E1 for mediating fusion; E2 for receptorbinding; E3 as a signal sequence for processing of E2 glycoprotein. Aten-residue detection tag sequence was inserted between amino acid 71and 74 of the E2 glycoprotein. A series of alterations (a4: deletion ofamino acids 61-64 of E3; a5: mutation of 68SLKQ71 into 68AAAA71; ab:mutation of 157KE158 into 157AA158) was introduced to yield the bindingdefective and fusion competent SINmu fusion molecule.

FIG. 3D is similar to the FACS analysis shown in FIG. 3B, except thatS1Nmu was used for the fusion protein and was detected by an anti-tagantibody.

FIG. 4A illustrates FACS analysis of target cell line 293T/CD20. CD20expression was detected using anti-CD20 antibody. The solid line showsexpression of CD20 in 293T/CD20; the shaded line shows CD20 expressionin 293T cells (as a control).

FIG. 4B is a schematic representation of a three-staining scheme usedfor analyzing virus-cell binding. Three stains were used to detect thepresence of CD20, ccCD20 and the fusogenic molecule (HAmu or SINmu),respectively.

FIG. 4C, left panel, illustrates FACS plots of 293T/CD20 cells incubatedwith FUGW/αCD20+HAmu. The binding of virus to 293T/CD20 cells was probedwith antibody against αCD20 (anti-IgG) and HAmu. The solid lineindicates analysis on 293T/CD20; the shaded line shows analysis on 293T(as a control). The right panel of FIG. 4C shows FACS plots of 293T/CD20cells incubated with FUGW/αCD20+S1Nmu. The binding of virus to 293T/CD20cells was detected by antibody against αCD20 and SINmu. The solid lineshows analysis on 293T/CD20; the shaded line shows analysis on 293T (asa control).

FIG. 4D illustrates co-display of antibody and fusogenic protein througha density plot correlating the presence of the two proteins.

FIG. 5A shows density plots illustrating targeting of recombinantlentivirus bearing both antibody and fusion protein to 293T/CD20 cellsin vitro. 293T/CD20 cells (2×10⁵) were transduced with 500 pL freshunconcentrated FUGW/αCD20 (no HAmu), FUGW/HAmu (no αCD20), orFUGW/αCD20+HAmu. 293T cells that did not express CD20 were included ascontrols. The resulting GFP expression was analyzed by FACS. Thespecific transduction titer for FUGW/αCD20+HAmu was estimated tobe—1×10⁵ TU/mL.

FIG. 5B illustrates results from a similar transduction experiment tothat shown in FIG. 5A, but performed using unconcentrated FUGW/S1Nmu (noαCD20) or FUGW/αCD20+SINmu. For comparison of targeting specificity,cells were also transduced with FUGW/HAmu. The specific transductiontiter for FUGW/αCD20+SINmu was estimated to be 1×10⁶ TU/mL.

FIG. 5C illustrates evidence of pH-dependent fusion of HAmu and SINmu bya cell-cell fusion assay. 293T cells (0.1×10⁶) transiently transfectedto express GFP and surface αCD20 and fusion protein (either HAmu orSINmu), and 293T/CD20 cells were mixed together, washed once with normalPBS (pH=7.4), and incubated in low pH PBS (pH=5.0) or normal pH PBS (asa control) for half an hour at 37° C. The cells were then washed andcultured in the regular medium for one day. Cells were visualized byepifluorescence microscope equipped with a GFP filter set.

FIG. 5D illustrates the effect of addition of soluble αCD20 ontransduction with viral particles displaying αCD20 and a fusogenicprotein. αCD20 was added into viral supernatants during transduction for8 hours. Then the supernatants were replaced with fresh medium. Thecells were analyzed for GFP expression after two days. Isotype-matchedantibody was used as a control.

FIG. 5E illustrates the pH dependence of transduction based on theeffect of addition of NH₄Cl (instead of soluble αCD20).

FIGS. 6A-6C shows the targeting of CD20⁺ human primary B cells in vitroand in vivo using engineered lentivirus. FIG. 6A illustrates expressionof a gene of interest (GFP) in fresh, unfractionated human PBMCs (2×10⁶)transduced by co-culturing with concentrated FUGW/αCD20+SINmu,CCMV/αCD20+SINmu or CPGK/αCD20+S1Nmu virus (10×10⁶ TU). LPS (50 μg/mL)was added into the culture media for B cell survival and growth. Aftertwo days, the B cell population was identified by co-staining of CD19and CD20. The solid line indicates expression in transduced cells; theshaded line shows expression in untransduced cells.

FIG. 6B shows stable integration of the transgene as detected by genomicPCR amplification using a pair of GFP-specific primers.

FIG. 6C shows expression of a gene of interest in target cells followingin vivo delivery of virus. Fresh human PBMCs were transferred intoirradiated RAG2^(−/−)7,^(−/−) mice (100×10⁶/mouse) via tail veininjection. Six hours later, concentrated virus (100×10⁶ TU/mouse) wasinjected through the tail vein. Two days later, whole blood wascollected from these mice via heart puncture and the cells were stainedfor human CD3 and CD20 and then analyzed by FACS for GFP expression. Inthe lower panels, the shaded line illustrates no virus treatment and thedashed line shows treatment with FUGW/b12+SINmu virus. The solid lineshows treatment with FUGW/αCD20+SINmu virus.

FIG. 7 illustrates expression of a gene of interest using virus preparedfrom three different viral constructs. Fresh, unfractionated human PBMCs(2×10⁶) were transduced by co-culturing with concentratedFUGW/αCD20+SINmu, CCMV/αCD20+S1Nmu or CPGK/a (CD20+SINmu (10×10⁶ TU).PMA (50 ng/mL) and ionomycin (500 ng/mL) was added into the culturemedia to enhance T cells survival and growth. After two days, the T cellpopulation was identified by co-staining of human CD3. The solid lineshows analysis on transduced cells; the shaded line illustrates analysison cells without transduction (as a control).

FIG. 8 illustrates a fluorescent microscopy examination of the infectionof dendritic cells using FUGW/αmDEC205+SINmu.

FIG. 9 illustrates a FACS analysis of DCs infected byFUGW/αmDEC-205+SINmu. Uninfection included as controls.

FIG. 10A shows a construct for expression of single chain antibody(scαCD20).

FIG. 10B shows a FACS analysis of scαCD20 expression on 293T cells.

FIG. 11 shows a FACS analysis of 293T/CD20 cells transduced withFUGW/scαCD20+SINmu.

FIG. 12 illustrates targeting of lentiviruses bearing CD20 and fusionprotein to 293T/αCD20 cells.

FIG. 13A shows constructs for expression of membrane-bound αCD20.

FIG. 13B shows a FACS analysis of αCD20 expression on 293T cells.

FIG. 14 illustrates schematically the lentiviral vector FUGW.

FIG. 15A illustrates the results of infection of c-kit-expressing D9cells with FUGW/mSCF+SINmu, E.G7 cells used as controls.

FIG. 15B illustrates the results of infection of c-kit-expressing TF-lacells with FUGW/mSCF+SINmu, E.G7 cells used as controls.

FIG. 16 illustrates the results of targeting retroviruses bearing SCFand SINmu to c-kit-expressing cells, E.G7 used as controls.

FIG. 17 illustrates FACS analysis of lentiviral particles bearing αCD20to bind 293T/CD20 cells.

DETAILED DESCRIPTION

Targeting efficient gene delivery vehicles to the desired cell typeswith specificity greatly enhances the therapeutic potential ofvirus-mediated gene therapy and alleviates concerns of off-targeteffects in vivo. In addition, it has many advantages in other contexts,such as in the generation of transgenic animals with particular traits,such as disease resistance or production of a protein in specifictissues.

The preferred embodiments of the methods and constructs described hereinare based, in part, on the finding that the viral binding and fusionfunctions can be separated into two distinct components (fusogenicproteins and affinity molecules) that are inserted into the viralenvelope. This allows precise targeting of virus to the desired targetcells and efficient transduction and delivery of a desiredpolynucleotide or other molecule. An advantage of this method overothers, for example those where viral fusion proteins are engineeredwith a foreign binding component, is that the fusion protein canmaintain its biological activity so that viral titer is not sacrificedfor increased target specificity.

As discussed in detail below, the methods are preferably based on theuse of recombinant retroviruses, such as lentiviruses, because theseviruses readily incorporate into their envelope whatever proteins arefound on the surface of virus-producing cells. However, other types ofviruses may be used and the methods modified accordingly. Generally, apackaging cell line is transfected with one or more vectors encoding theretroviral components, a gene of interest, a fusion molecule and anaffinity molecule. During budding of the virus the fusion molecule andaffinity molecule, which have been expressed in the packaging cellmembrane, are incorporated into the viral envelope (FIG. 1). As aresult, the retroviral particles comprise a core including the gene ofinterest and an envelope comprising the fusion molecule and the affinitymolecule on its surface. The affinity molecule then recognizes aconstituent of the target cell membrane and attaches the lentivirus tothe cell surface (FIG. 2). The binding induces endocytosis of thetarget, bringing the lentivirus into an endosome. There, the fusogenicmolecule (FM) triggers membrane fusion, allowing the virus core to enterthe cytosol. Following reverse transcription and migration of theproduct to the nucleus, the genome of the virus integrates into thetarget cell genome, incorporating the transgene.

The methods disclosed herein may be readily adopted to a variety ofaffinity molecules and fusogenic molecules. In a preferred embodiment,the fusion molecule (FM) is preferably a viral glycoprotein thatmediates fusion, preferably in response to the low pH environment of theendosome, and the affinity molecule is preferably a membrane-boundprotein that is efficiently endocytosed after binding. The fusionmolecule preferably exhibits fast enough kinetics that the viralcontents can empty into the cytosol before the degradation of the viralparticle. In addition, the fusion molecule can be modified to reducetheir binding ability and thus reduce or eliminate any non-specificbinding. That is, by reducing the binding ability of the fusionmolecules, binding of the virus to the target cell is determinedpredominantly or entirely by the affinity molecule, allowing for hightarget specificity and reducing undesired effects.

Affinity molecules may include, for example, antibodies to a particularantigen on the target cell surface, as well as receptors for cellsurface ligands or ligands for cell surface receptors. The affinitymolecules are preferably membrane bound. Thus, if an antibody is to beused it may be modified to membrane bound form. For example, thevariable regions from an antibody with the desired specificity can becloned into IgG₁. Alternatively, a transmembrane domain may be attachedto an antibody, such as a single chain antibody.

In some embodiments, the methods are used to target dendritic cellsusing a membrane-bound monoclonal antibody against the DEC-205 receptoras the affinity molecule. In other embodiments, incorporation of amembrane-bound form of stem cell factor as the affinity molecule may beused to target c-kit-positive cells.

The modular flexibility (combination of affinity molecule and fusogenicmolecule) and breadth (availability of, for example, monoclonalantibodies or ligands for many endocytosed cell-specific surfacemolecules, and the ability to generate such antibodies) of the disclosedmethod is thus especially advantageous in facilitating the applicationof targeted gene delivery for therapy, industry and research. Forexample, the methods of the present invention may be used to targettumor cells and deliver a toxic gene. In another embodiment, cellsinfected by a pathogen (or susceptible to such infection) may betargeted to deliver siRNA to inhibit a stage in the pathogen's lifecycle. In still another embodiment, a cell lacking a particularcomponent (e.g., an enzyme) may be targeted to deliver a gene encodingfor that particular component.

Definitions

Unless defined otherwise, technical and scientific terms used hereinhave the same meaning as commonly understood by one of ordinary skill inthe art to which this invention belongs. See, e.g., Singleton et al.,Dictionary of Microbiology and Molecular Biology 2nd ed., J. Wiley &Sons (New York, N.Y. 1994); Sambrook et al., Molecular Cloning, ALaboratory Manual, Cold Springs Harbor Press (Cold Springs Harbor, N Y1989). Any methods, devices and materials similar or equivalent to thosedescribed herein can be used in the practice of this invention.

As used herein, the terms nucleic acid, polynucleotide and nucleotideare interchangeable and refer to any nucleic acid, whether composed ofphosphodiester linkages or modified linkages such as phosphotriester,phosphoramidate, siloxane, carbonate, carboxymethylester, acetamidate,carbamate, thioether, bridged phosphoramidate, bridged methylenephosphonate, bridged phosphoramidate, bridged phosphoramidate, bridgedmethylene phosphonate, phosphorothioate, methylphosphonate,phosphorodithioate, bridged phosphorothioate or sultone linkages, andcombinations of such linkages.

The terms nucleic acid, polynucleotide and nucleotide also specificallyinclude nucleic acids composed of bases other than the five biologicallyoccurring bases (adenine, guanine, thymine, cytosine and uracil).

As used herein, a nucleic acid molecule is said to be “isolated” whenthe nucleic acid molecule is substantially separated from contaminantnucleic acid molecules encoding other polypeptides.

“Immunization” refers to the provision of antigen to a host. In someembodiments, antigen is provided to antigen-presenting cells, such asdendritic cells. For example, as described below, recombinant viruscomprising a gene encoding an antigen can be targeted to dendritic cellswith an affinity molecule specific to a protein on dendritic cells. Thusthe antigen to which an immune response is desired can be delivered tothe dendritic cells. Other methods of immunization are well known in theart.

“Antibodies” (Abs) and “immunoglobulins” (Igs) are glycoproteins havingthe same structural characteristics. While antibodies exhibit bindingspecificity to a specific antigen, immunoglobulins include bothantibodies and other antibody-like molecules that lack antigenspecificity. Polypeptides of the latter kind are, for example, producedat low levels by the lymph system and at increased levels by myelomas.

“Native antibodies” and “native immunoglobulins” are usuallyheterotetrameric glycoproteins, composed of two identical light (L)chains and two identical heavy (H) chains. Each light chain is linked toa heavy chain by a disulfide bond. The number of disulfide linkagesvaries among the heavy chains of different immunoglobulin isotypes. Eachheavy chain comprises a variable domain (V_(H)) followed by a number ofconstant domains. Each light chain comprises a variable domain at oneend (V_(L)) and a constant domain at its other end. The constant domainof the light chain is aligned with the first constant domain of theheavy chain, and the light chain variable domain is aligned with thevariable domain of the heavy chain.

The term “antibody” is used in the broadest sense and specificallycovers human, non-human (e.g. murine) and humanized monoclonalantibodies (including full length monoclonal antibodies), polyclonalantibodies, multi-specific antibodies (e.g., bispecific antibodies),single-chain antibodies, and antibody fragments so long as they exhibitthe desired biological activity.

“Target cells” are any cells in which expression of a gene of interestis desired. Preferably, target cells exhibit a protein or other moleculeon their surface that allows the cell to be targeted with an affinitymolecule, as described below.

The term “mammal” is defined as an individual belonging to the classMammalia and includes, without limitation, humans, domestic and farmanimals, and zoo, sports, and pet animals, such as sheep, dogs, horses,cats and cows.

A “subject” or “patient” is any animal, preferably a mammal, that is inneed of treatment.

As used herein, “treatment” is a clinical intervention made in responseto a disease, disorder or physiological condition manifested by apatient or to be prevented in a patient. The aim of treatment includesthe alleviation and/or prevention of symptoms, as well as slowing,stopping or reversing the progression of a disease, disorder, orcondition. “Treatment” refers to both therapeutic treatment andprophylactic or preventative measures. Those in need of treatmentinclude those already affected by a disease or disorder or undesiredphysiological condition as well as those in which the disease ordisorder or undesired physiological condition is to be prevented.“Treatment” need not completely eliminate a disease, nor need itcompletely prevent a subject from catching the disease or disorder.

“Tumor,” as used herein, refers to all neoplastic cell growth andproliferation, whether malignant or benign, and all pre-cancerous andcancerous cells and tissues.

The term “cancer” refers to a disease or disorder that is characterizedby unregulated cell growth. Examples of cancer include, but are notlimited to, carcinoma, lymphoma, blastoma and sarcoma. Examples ofspecific cancers include, but are not limited to, lung cancer, coloncancer, breast cancer, testicular cancer, stomach cancer, pancreaticcancer, ovarian cancer, liver cancer, bladder cancer, colorectal cancer,and prostate cancer. Additional cancers are well known to those of skillin the art.

A “vector” is a nucleic acid that is capable of transporting anothernucleic acid. Vectors may be, for example, plasmids, cosmids or phage.An “expression vector” is a vector that is capable of directingexpression of a protein encoded by one or more genes carried by thevector when it is present in the appropriate environment.

The term “regulatory element” and “expression control element” are usedinterchangeably and refer to nucleic acid molecules that can influencethe transcription and/or translation of an operably linked codingsequence in a particular environment. These terms are used broadly andcover all elements that promote or regulate transcription, includingpromoters, core elements required for basic interaction of RNApolymerase and transcription factors, upstream elements, enhancers, andresponse elements (see, e.g., Lewin, “Genes V” (Oxford University Press,Oxford) pages 847-873). Exemplary regulatory elements in prokaryotesinclude promoters, operator sequences and a ribosome binding sites.Regulatory elements that are used in eukaryotic cells may include,without limitation, promoters, enhancers, splicing signals andpolyadenylation signals.

The term “transfection” refers to the introduction of a nucleic acidinto a host cell.

“Retroviruses” are viruses having an RNA genome.

“Lentivirus” refers to a genus of retroviruses that are capable ofinfecting dividing and non-dividing cells. Several examples oflentiviruses include HIV (human immunodeficiency virus: including HIVtype 1, and HIV type 2), the etiologic agent of the human acquiredimmunodeficiency syndrome (AIDS); visna-maedi, which causes encephalitis(visna) or pneumonia (maedi) in sheep, the caprinearthritis-encephalitis virus, which causes immune deficiency, arthritis,and encephalopathy in goats; equine infectious anemia virus, whichcauses autoimmune hemolytic anemia, and encephalopathy in horses; felineimmunodeficiency virus (FIV), which causes immune deficiency in cats;bovine immune deficiency virus (BIV), which causes lymphadenopathy,lymphocytosis, and possibly central nervous system infection in cattle;and simian immunodeficiency virus (SIV), which cause immune deficiencyand encephalopathy in sub-human primates.

A “hybrid virus” as used herein refers to a virus having components fromone or more other viral vectors, including element from non-retroviralvectors, for example, adenoviral-retroviral hybrids. As used hereinhybrid vectors having a retroviral component are to be considered withinthe scope of the retroviruses.

A lentiviral genome is generally organized into a 5′ long terminalrepeat (LTR), the gag gene, the pol gene, the env gene, the accessorygenes (nef, vif, vpr, vpu) and a 3′ LTR. The viral LTR is divided intothree regions called U3, R and U5. The U3 region contains the enhancerand promoter elements. The U5 region contains the polyadenylationsignals. The R (repeat) region separates the U3 and U5 regions andtranscribed sequences of the R region appear at both the 5′ and 3′ endsof the viral RNA. See, for example, “RNA Viruses: A Practical Approach”(Alan J. Cann, Ed., Oxford University Press, (2000)), 0 Narayan andClements J. Gen. Virology 70:1617-1639 (1989), Fields et al. FundamentalVirology Raven Press. (1990), Miyoshi H, Blomer U, Takahashi M, Gage FH, Verma I M. J Virol. 72(10):8150-7 (1998), and U.S. Pat. No.6,013,516.

Lentiviral vectors are known in the art, including several that havebeen used to transfect hematopoietic stem cells. Such vectors can befound, for example, in the following publications, which areincorporated herein by reference: Evans J T et al. Hum Gene Ther 1999;10:1479-1489; Case S S, Price M A, Jordan C T et al. Proc Natl Acad SciUSA 1999; 96:2988-2993; Uchida N, Sutton R E, Friera A M et al. ProcNatl Acad Sci USA 1998; 95:11939-11944; Miyoshi H, Smith K A, Mosier D Eet al. Science 1999; 283:682-686; Sutton R E, Wu H T, Rigg R et al.Human immunodeficiency virus type 1 vectors efficiently trans duce humanhematopoietic stem cells. J Virol 1998; 72:5781-5788.

“Virion,” “viral particle” and “retroviral particle” are used herein torefer to a single virus comprising an RNA genome, pol gene derivedproteins, gag gene derived proteins and a lipid bilayer displaying anenvelope (glyco)protein. The RNA genome is usually a recombinant RNAgenome and thus may contain an RNA sequence that is exogenous to thenative viral genome. The RNA genome may also comprise a defectiveendogenous viral sequence.

A “pseudotyped” retrovirus is a retroviral particle having an envelopeprotein that is from a virus other than the virus from which the RNAgenome is derived. The envelope protein may be from a differentretrovirus or from a non-retroviral virus. A preferred envelope proteinis the vesicular stomatitius virus G (VSV G) protein. However, toeliminate the possibility of human infection, viruses can alternativelybe pseudotyped with an ecotropic envelope protein that limits infectionto a specific species, such as mice or birds. For example, in oneembodiment, a mutant ecotropic envelope protein is used, such as theecotropic envelope protein 4.17 (Powell et al. Nature Biotechnology18(12):1279-1282 (2000)).

A “self-inactivating 3′ LTR” is a 3′ long terminal repeat (LTR) thatcontains a mutation, substitution or deletion that prevents the LTRsequences from driving expression of a downstream gene. A copy of the U3region from the 3′ LTR acts as a template for the generation of bothLTR's in the integrated provirus. Thus, when the 3′ LTR with aninactivating deletion or mutation integrates as the 5′ LTR of theprovirus, no transcription from the 5′ LTR is possible. This eliminatescompetition between the viral enhancer/promoter and any internalenhancer/promoter. Self-inactivating 3′ LTRs are described, for example,in Zufferey et al. J. Virol. 72:9873-9880 (1998), Miyoshi et al. J.Virol. 72:8150-8157 and Iwakuma et al. Virology 261:120-132 (1999).

“Transformation,” as defined herein, describes a process by whichexogenous DNA enters a target cell. Transformation may rely on any knownmethod for the insertion of foreign nucleic acid sequences into aprokaryotic or eukaryotic host cell and may include, but is not limitedto, viral infection, electroporation, heat shock, lipofection, andparticle bombardment. “Transformed” cells include stably transformedcells in which the inserted DNA is capable of replication either as anautonomously replicating plasmid or as part of the host chromosome. Alsoincluded are cells that transiently express a gene of interest.

A “fusogenic molecule,” as described herein, is any molecule on a viralsurface that triggers membrane fusion, and allows the virus core to passthrough the membrane and, typically, enter the cytosol of a target cell.Viral glycoproteins are one example of fusogenic molecules.

An “affinity molecule,” or “cell-specific binding determinant” asdescribed herein, is any molecule on a viral surface that functions torecognize a molecular constituent on a target cell membrane and therebytarget the virus to the cell surface. The affinity molecule is mostpreferably discrete from the fusogenic molecule.

By “transgene” is meant any nucleotide sequence, particularly a DNAsequence, that is integrated into one or more chromosomes of a host cellby human intervention, such as by the methods of the present invention.The transgene preferably comprises a “gene of interest.” In otherembodiments the transgene can be a nucleotide sequence, preferably a DNAsequence, that is used to mark the chromosome where it has integrated.The transgene does not have to comprise a gene that encodes a proteinthat can be expressed.

A “gene of interest” is not limited in any way and may be any nucleicacid, without limitation, that is desired to be integrated, transcribed,translated, and/or expressed in a target cell. The gene of interest mayencode a functional product, such as a protein or an RNA molecule.Preferably the gene of interest encodes a protein or other molecule theexpression of which is desired in the host cell. The gene of interest isgenerally operatively linked to other sequences that are useful forobtaining the desired expression of the gene of interest, such astranscriptional regulatory sequences.

A “functional relationship” and “operably linked” mean, withoutlimitation, that the gene is in the correct location and orientationwith respect to the promoter and/or enhancer that expression of the genewill be affected when the promoter and/or enhancer is contacted with theappropriate molecules.

An “RNA coding region” is a nucleic acid that can serve as a templatefor the synthesis of an RNA molecule, such as an siRNA. Preferably, theRNA coding region is a DNA sequence.

A “small interfering RNA” or “siRNA” is a double-stranded RNA moleculethat is capable of inhibiting the expression of a gene with which itshares homology. In one embodiment the siRNA may be a “hairpin” orstem-loop RNA molecule, comprising a sense region, a loop region and anantisense region complementary to the sense region. In other embodimentsthe siRNA comprises two distinct RNA molecules that are non-covalentlyassociated to form a duplex.

“2A sequences” or elements are small peptides introduced as a linkerbetween two proteins, allowing autonomous intraribosomal self-processingof polyproteins (de Felipe. Genetic Vaccines and Ther. 2:13 (2004);deFelipe et al. Traffic 5:616-626 (2004)). The short peptides allowco-expression of multiple proteins from a single vector, such asco-expression of a fusogenic molecule and affinity molecule from thesame vector. Thus, in some embodiments polynucleotides encoding the 2Aelements are incorporated into a vector between polynucleotides encodingproteins to be expressed.

Fusogenic Molecules

Fusogenic molecules (FMs) are molecules that are able to be incorporatedin the envelope of recombinant viruses and, under the right conditions,induce membrane fusion allowing entry of a gene of interest to a targetcell. Fusogenic molecules preferably are able to pseudotype virus,preferably recombinant lentivirus and thus are able to be incorporatedin the viral envelope. Preferably, the FM does not mediate viralinfection of target cells directly, but still maintains its capabilityto induce fusion once a virus enters the endocytic pathways. Thus, whileFMs may natively have the ability to bind a cell surface molecule, FMswith low or reduced binding ability are preferred to reduce non-specifictransduction. Preferred FMs are viral glycoproteins. In addition, FMsare preferably resistant to ultracentrifugation to allow concentration,which is important for in vivo gene delivery.

FMs preferably induce membrane fusion at a low pH, independently ofaffinity molecule binding. Thus, in the disclosed methods FM inducedmembrane fusion preferably occurs once the virus comprising the FM isinside the endosome of a target cell and the viral core component,including a gene of interest, is delivered to the cytosol.

In some embodiments a tag sequence is incorporated into the fusogenicmolecule to allow detection of FM expression and the presence of the FMin viral particles.

There are two recognized classes of viral fusogens and both can be usedas FMs (D. S. Dimitrov, Nature Rev. Microbio. 2, 109 (2004)). The classI fusogens trigger membrane fusion using helical coiled-coil structureswhereas the class II fusogens trigger fusion with 13 barrels. These twostructures have different mechanics and kinetics (D. S. Dimitrov, NatureRev. Microbio. 2, 109 (2004)).

Some non-limiting examples of surface glycoproteins that may be used asfusion molecules include glycoproteins from alphaviruses, such asSemliki Forest virus (SFV), Ross River virus (RRV) and Aura virus (AV),which comprise surface glycoproteins such as E1, E2, and E3. The E2glycoproteins derived from the Sindbis virus (SIN) and the hemagglutinin(HA) of influenza virus are non-retroviral glycoproteins that recognizeparticular molecules on cell surfaces (heparin sulfate glycosaminoglycanfor E2, sialic acid for HA) and are used as FMs in some embodiments.Their fusion is relatively independent of binding to receptor molecules,and the activation of fusion is accomplished through acidification inthe endosome (Skehel and Wiley, Annu. Rev. Biochem. 69, 531-569 (2000);Smit, J. et al. J. Virol. 73, 8476-8484 (1999)). Moreover, they cantolerate certain genetic modifications and remain efficiently assembledon the retroviral surface (Morizono et al. J. Virol. 75, 8016-8020).Because of the ubiquitous presence of surface molecules recognized bysome FMs, binding-defective but fusion competent fusogenic proteins arepreferably used, such as a binding-defective form of HA.

In other embodiments of the invention, surface glycoproteins of Lassafever virus, Hepatitis B virus, Rabies virus, Borna disease virus,Hantaan virus, or SARS-CoV virus may also be utilized as fusionmolecules. In other embodiments, DV glycoprotein may be utilized as afusion molecule.

In other embodiments of the invention, flavivirus-based surfaceglycoproteins may be used as fusion molecules. Like alphaviruses,flaviviruses use the class II fusion molecule to mediate infection(Mukhopadhyay et al. (2005) Rev. Microbio. 3, 13-22). prM (about 165amino acids) and E (about 495 amino acids) are the glycoproteins offlaviviruses. Also, the ligand-binding pocket for DV has beenwell-characterized. Of interest, DC-SIGN (dendritic-cell-specificICAM-grabbing non-integrin), a mannose-specific lectin, has beensuggested to specifically interact with the carbohydrate residues on theDV E protein to enhance viral entry (Mukhopadhyay et al. (2005) Nat.Rev. Microbio. 3, 13-22). This, lentiviruses enveloped only by DV Eprotein can potentially target DCs. The ligand-binding pockets of TBEand DV E proteins, as well as other fusion molecules described, may beengineered to be binding deficient and fusion competent in the followingmanner.

In some embodiments, hemagglutinin (HA) from influenza A/fowl plaguevirus/Rostock/34 (FPV), a class I fusogen, is used. (T. Hatziioannou, S.Valsesia-Wittmann, S. J. Russell, F. L. Cosset, J. Virol. 72, 5313(1998)). Preferably, a binding defective version of FPV HA, such as HAmu(FIG. 3A), is used (A. H. Lin et al., Hum. Gene. Ther. 12, 323 (2001)).HAmu-mediated fusion is generally considered to be independent ofreceptor binding (D. Lavillette, S. J. Russell, F. L. Cosset, Curr.Opin. Biotech. 12, 461 (2001)).

In other embodiments, a class II FM is used, preferably the Sindbisvirus glycoprotein from the alphavirus family (K. S. Wang, R. J. Kuhn,E. G. Strauss, S. Ou, J. H. Strauss, J. Virol. 66, 4992 (1992)), hereinalso referred to as SIN. SIN includes two transmembrane proteins (S.Mukhopadhyay, R. J. Kuhn, M. G. Rossmann, Nature Rev. Microbio. 3, 13(2005)), a first protein responsible for fusion (E1), and a secondprotein for cell binding (E2). SIN is known to pseudotype bothoncoretroviruses and lentiviruses.

In some embodiments a binding-deficient and fusion-competent SIN is usedas the fusogenic molecule. For example, a SIN fusogenic molecule can beused in which the immunoglobulin G binding domain of protein A (ZZdomain) is incorporated into the E2 protein and one or more additionalmutations are made to inactivate the receptor binding sites (K. Morizonoet al., Nature Med. 11, 346 (2005)).

The gene encoding the FM is preferably cloned into an expression vector,such as pcDNA3 (Invitrogen). Packaging cells, such as 293T cells arethen co-transfected with the viral vector comprising the gene ofinterest, a packaging vector (if necessary), one or more vectorsencoding an affinity molecule and any associated components, and thevector for expression of the fusogenic molecule. The FM is expressed onthe membrane of the packaging cell and incorporated into the recombinantvirus. Expression of envelope glycoprotein on the packaging cell surfacemay be analyzed by FACS.

Based on information obtained, for example from structural studies andmolecular modeling, mutagenesis may be employed to generate the mutantforms of glycoproteins that maintain their fusogenic ability but havethe desired level of binding. Several mutants may be created for eachglycoprotein and assayed using the methods described below, or othermethods known in the art, to identify FMs with the most desirablecharacteristics.

To select suitable FMs (either wild-type or mutant), viruses bearingboth the FM and an affinity molecule are prepared and tested for theirselectivity and/or their ability to facilitate penetration of the targetcell membrane. Viruses that do not display the affinity molecule may beused as controls for measuring selectivity, while viruses displaying theaffinity molecule and wild-type glycoprotein can be used as controls forexamining titer effects in mutants. Cells expressing the binding partnerof the affinity molecule are transduced by the virus using a standardinfection assay. After a specified time, for example, 48 hourspost-transduction, cells can be collected and the percentage of cellsinfected by the virus comprising the mutant FM can be determined by, forexample, FACS. The selectivity can be scored by calculating thepercentage of cells infected by virus. Similarly, the effect ofmutations on viral titer can be quantified by dividing the percentage ofcells infected by virus comprising a mutant FM by the percentage ofcells infected by virus comprising the corresponding wild type FM. Apreferred mutant will give the best combination of selectivity andinfectious titer. Once an FM is selected, viral concentration assays maybe performed to confirm that viruses enveloped by the FM can beconcentrated. Viral supernatants are collected and concentrated byultracentrifugation. The titers of viruses can be determined by limiteddilution of viral stock solution and transduction of cells expressingthe binding partner of the affinity molecule.

In some embodiments, B1aM-Vpr fusion protein may be utilized to evaluateviral penetration, and thus the efficacy of a fusion molecule (wild-typeor mutant). An affinity molecule, such as an antibody, may envelopeviral particles incorporating B1aM-Vpr. Such virus may be prepared, forexample, by transient transfection of packaging cells with one or morevectors comprising the viral elements, B1aM-Vpr, the FM of interest andan affinity molecule. The resulting viruses can be used to infect cellsexpressing a molecule recognized by the affinity molecule in the absenceor presence of the free inhibitor of affinity molecule binding (such asan antibody). Cells can then be washed with CO₂-independent medium andloaded with CCF2 dye (Aurora Bioscience). After incubation at roomtemperature to allow completion of the cleavage reaction, the cells canbe fixed by paraformaldehyde and analyzed by FACS and microscopy. Thepresence of blue cells indicates the penetration of viruses into thecytoplasm; fewer blue cells would be expected when blocking antibody isadded.

To investigate whether penetration is dependent upon a low pH, andselect FM with the desired pH dependence, NH₄Cl or other compound thatalters pH can be added at the infection step (NH₄Cl will neutralize theacidic compartments of endosomes). In the case of NH₄Cl, thedisappearance of blue cells will indicate that penetration of viruses islow pH-dependent.

In addition, to confirm that the fusion molecule activity ispH-dependent, lysosomotropic agents, such as ammonium chloride,chloroquine, concanamycin, bafilomycin A1, monensin, nigericin, etc.,may be added into the incubation buffer. These agents can elevate the pHwithin the endosomal compartments (e.g., Drose and Altendorf, J. Exp.Biol. 200, 1-8, 1997). The inhibitory effect of these agents will revealthe role of pH for viral fusion and entry. The different entry kineticsbetween viruses displaying different fusogenic molecules may be comparedand the most suitable selected for a particular application.

PCR entry assays may be utilized to monitor reverse transcription andthus measure kinetics of viral DNA synthesis as an indication of thekinetics of viral entry. For example, viral particles comprising aparticular FM and an affinity molecule may be incubated with packagingcells, such as 293T cells, expressing the appropriate cognate for theaffinity molecule. Either immediately, or after incubation (to allowinfection to occur) unbound viruses are removed and aliquots of thecells are analyzed. DNA may then be extracted from these aliquots andsemi-quantitative performed using LTR-specific primers. The appearanceof LTR-specific DNA products will indicate the success of viral entryand uncoating.

Cell-Specific Binding Determinants (Membrane-Bound Affinity Molecules)

In preferred embodiments of the invention, the viral surface comprises acell-specific binding determinant comprising a membrane-bound affinitymolecule. The affinity molecule is selected to bind selectively to asurface molecule, for example, a receptor protein, on a target cell.Preferably, the binding is high-affinity binding and in some embodimentsthe dissociation constant may be in the range of 10⁻⁶ to 10⁻¹² M.However, in other embodiments lower or higher affinity binding ispossible.

Generally, the target cell protein is one that is expressed selectivelyon the target cells. That is, the target cell protein is preferablyexpressed exclusively on target cells or expressed on target cells at ahigher concentration than on other cells. However, in some embodimentswhere a wide population of target cells is to be targeted, a target cellprotein may be expressed in a variety of cell types, or evenubiquitously expressed.

The affinity molecule is preferably a membrane-bound ligand, membranebound receptor, or a membrane bound antibody, such as, withoutlimitation, a chimeric antibody, an antibody fragment or a single chainantibody. Although referred to generally in the singular, the affinitymolecule may comprise two or more molecules, such as an IgG₁ and the Igαand Igβ molecules.

The membrane-bound affinity molecule is most preferably a separatemolecule from the fusogenic molecule.

Upon binding of the affinity molecule to a molecule on the target cellsurface, the virus particle is taken up by endocytosis. In someembodiments, a pH change then induces the fusion molecule to fuse andallows the delivery of the viral core across the membrane and into thecytosol.

The affinity molecule is co-expressed in the packaging cell with thevirus comprising the gene of interest and a fusogenic molecule.Constructs for expressing the affinity molecule in the packaging cellalso may include, in some embodiments, sequences encoding necessarysignal peptides to direct the protein to be expressed on the cellsurface.

Packaging cells, such as 293T cells, are preferably co-transfected withthe viral vector comprising the gene of interest, a packaging vector (ifnecessary), one or more vectors encoding the affinity molecule and anyassociated components (such as Igα and Igβ), and the vector forexpression of the fusogenic molecule. In some embodiments, two or moreof these components are combined in a multi-cistronic expression vector.For example, in some embodiments the fusogenic molecules and theaffinity molecule are included in the same vector.

The affinity molecule is expressed on the membrane of the packaging celland incorporated into the envelope of the recombinant virus. Expressionof the affinity molecule may be assayed by known methods, such as withan antibody to the affinity molecule.

The ability of various types of affinity molecules (such as antibodiesto different epitopes of the target protein) to facilitate targeting ofthe recombinant retrovirus and gene delivery can be compared and themolecule with the most desirable characteristics can be selected.Desirable characteristics include, for example, the ability to stimulateefficient endocytosis of the virus, the ability to bind the targetmolecule with specificity and, similarly, the ability to facilitatebinding of the recombinant virus to the target cell. For example, thesame target bound by different affinity molecules can be endocytoseddifferently. Thus, in some embodiments, an affinity molecule with theability to trigger endocytosis while maintaining binding specificity fora particular target cell type is selected. Similarly, the sameantibody-antigen pair could stimulate different endocytosis pathways indifferent cells, leading to a different ability to facilitate deliveryof the gene of interest in the different cells. The assays discussedabove with respect to the fusogenic molecule can be modified to comparethe abilities of various antibodies, or other affinity molecules, tomediate delivery of a gene of interest to a particular target cell.

The transduction efficiency mediated by different affinity molecules,for example, different anti-CD20 antibodies in different cells, canreadily be tested. Transduction can be performed in cells most closelyresembling the target cells (or the target cells if available) andefficiency of viral entry quantified and compared. The aboveBa1M-Vpr-based assay and PCR-based assay may be employed to measure theefficiency of viral entry for the different affinity molecules indifferent cell lines. Furthermore, confocal microscopy can be utilizedto investigate the endocytosis induced by different affinity moleculesand in different cell types. These detailed studies can assist indetermining correlation between transduction efficiency and endocytosisbehavior, which can be used to optimize targeting schemes.

Antibodies as Affinity Molecules

In some embodiments the cell-specific binding determinant is anantibody. Antibodies may be generated against any desired cell surfacemolecule on target cells using well known methods. Antibodies may begenerated in an appropriate species to minimize immune response. Inother embodiments humanized or chimeric antibodies are prepared andused. For example, antibodies may be generated in a mouse, rabbit orother animal and the variable regions combined with the constant regionsof a human antibody. In addition, many antibodies are commerciallyavailable and can be selected based on the target molecule on the targetcells.

The cell-specific binding determinant is preferably membrane bound orotherwise associated with the membrane of the packaging cell andultimately the envelope of the recombinant virus. Thus, when theaffinity molecule is a soluble antibody it may be necessary to modifythe antibody to cause it to associate with the membrane.

In some preferred embodiments, an antibody used as an affinity moleculepreferably includes variable regions from an antibody to the target andconstant regions from human IgG₁ That is, the variable regions of anantibody to the target, such as a soluble antibody are combined with theconstant regions of IgG₁ to make a membrane bound chimericimmunoglobulin with the desired specificity. If the recombinantretrovirus is to be used in humans, the IgG₁ is preferably human.Methods for preparing chimeric antibodies are well known in the art.

In such embodiments the packaging cell (used to assemble the virus) ispreferably cotransfected with vectors encoding both the heavy and lightchains of IgG₁ along with vectors for the expression of immunoglobulinalpha (Igα) and immunoglobulin beta (Igβ). Immunoglobulin alpha (Igα)and immunoglobulin beta (Igβ) help to bind the antibody to the surfacemembrane of the virus. In some embodiments the antibody is generated ina species other than human, such as mouse or rabbit, and the variableregions are cloned into human IgG₁.

In some embodiments, a multicistronic vector is used to directexpression of an antibody and Igα and Igβ. Assembly PCR may be employedto link the antibody heavy chain, light chain, and Igα and Igβ. In oneembodiment the genes encoding the three components are separated bythree 2A peptides, to facilitate expression from a single promoter.Then, the entire cassette can be cloned into an expression vector suchas pCDNA3 (Invitrogen). The efficiency of antibody expression on thesurface of packaging cells can be analyzed by FACS staining.

In other embodiments, the affinity molecule is a single chain antibody,either natural or chimeric, and is preferably fused with a transmembranedomain from another protein (Chou et. al., Biotechnol. Bioeng., 65, 160(1999); Liao et al, Biotechnol. Bioeng., 73, 313 (2001); de Ines et al,J. Immunol., 163, 3948 (1999); Lee et al, J. Immunol., 173, 4618(2004)). A single chain membrane-bound form of antibody (scAbm) isadvantageous in simplifying viral production because display of thenatural form of an antibody on the cell surface requires co-expressionof four genes: antibody heavy chain, antibody light chain, Igα and Igβ.

scAbms are typically designed to have heavy chain and light chainvariable domains linked by a flexible peptide linker. They also carry asignal peptide at their N terminus and a transmembrane domain at their Cterminus for anchoring to the cell surface. In some embodiments aslightly different version of scAbm is used, comprising heavy chain andlight chain variable domains of the desired antibody (specific to anantigen on the target cell surface) linked by a peptide such as the(GGGGSGGGS)₂ peptide, and a dimerization region including the hingeCH2-CH3 domain of human IgG1, and the transmembrane domain and thecytoplasmic tail of the human HLA-A2 to display this chimeric protein onthe cell surface.

Thus, in some embodiments a target molecule is identified that isexpressed, preferably exclusively or predominantly, on a desired targetcell or cell population. Antibodies to the target molecule are generatedusing standard methods and the variable regions are combined with theconstant regions of human IgG₁ to form an affinity molecule to directthe recombinant retrovirus to the target cells with specificity.

Non-Antibody Affinity Molecules

In other embodiments, the affinity molecule can be a ligand, preferablya peptide or protein ligand, that binds to a cell surface receptor on atarget cell, a receptor that binds to a cell-surface ligand on a targetcell. When the affinity molecule is a soluble ligand or receptor, theaffinity molecule is preferably constructed as a fusion with atransmembrane domain or other component to anchor it to the membrane.Suitable ligands include, for example, hormones, growth factors, and thelike. One specific example of a non-antibody affinity molecule is stemcell factor.

While the affinity molecule can be a naturally occurring molecule, itcan also be a non-natural protein, for example, one specifically createdto bind to a particular protein on a target cell. In addition, theaffinity molecule is not limited to proteins, but could comprise anycompound that is able to specifically interact with a molecule on thetarget cell in such a way as to allow endocytosis of the viral particleinto the target cell. For example, in some embodiments the affinitymolecule may comprise a carbohydrate.

Delivery Vectors

In a preferred embodiment, one or more vectors are used to introduce thedesired polynucleotides into the target cell. The vectors comprise thepolynucleotide sequences encoding the various components of therecombinant retrovirus itself, the gene(s) of interest, the fusogenicmolecule and affinity molecule, and any components necessary for theproduction of the virus that are not provided by the packaging cell.These polynucleotides are typically under the control of one or moreregulatory elements that direct the expression of the coding sequencesin the packaging cell and the target cell, as appropriate. Eukaryoticcell expression vectors are well known in the art and are available froma number of commercial sources.

In some embodiments, packaging cells are transfected with a viral vector(as discussed below) along with two or more additional vectors. Forexample, in addition to the viral vector a second vector preferablycarries a gene encoding a fusogenic molecule, such as HAmu or SINmu, asdescribed elsewhere in the application. A third vector preferablycarries a gene encoding an affinity molecule, such as an antibody, asdescribed elsewhere in the application. Furthermore, in someembodiments, one or more additional vectors preferably include genesencoding packaging cell requirements, for example, viral envelopeproteins such as pol, env, and gag. Also, in some embodiments, such aswhere the affinity molecule is an IgG₁ immunoglobulin, one or morefurther vectors are used that encode accessory proteins, such as genesencoding Igα and Igβ.

In other embodiments, one or more multicistronic expression vectors areutilized that include two or more of the elements (e.g., the viralgenes, gene(s) of interest, the FM, affinity molecule, Igα, Igβ)necessary for production of the desired recombinant retrovirus inpackaging cells. The use of multicistronic vectors reduces the totalnumber of vectors required and thus avoids the possible difficultiesassociated with coordinating expression from multiple vectors. In amulticistronic vector the various elements to be expressed are operablylinked to one or more promoters (and other expression control elementsas necessary). For example, in one embodiment a multicistronicexpression vector is used to express an antibody affinity molecule andassociated components. The vector preferably comprises polynucleotidesencoding the antibody heavy and light chain and Igα and Igβ. In otherembodiments a multicistronic vector comprising a gene of interest, areporter gene, and viral elements is used. Such a vector may becotransfected, for example, along with a multicistronic vector encodingboth the FM and affinity molecules.

Each component to be expressed in a multicistronic expression vector maybe separated by a an IRES element or a viral 2A element to allow forseparate expression of the various proteins from the same promoter. IRESelements and 2A elements are known in the art (U.S. Pat. No. 4,937,190;de Felipe et al. Traffic 5:616-626 (2004)). In one embodiment,oligonucleotides encoding furin cleavage site sequences (RAKR) (Fang etal. Nat. Biotech 23, 584-590 (2005)) linked with 2A-like sequences fromfoot-and-mouth diseases virus (FMDV), equine rhinitis A virus (ERAV),and thosea asigna virus (TaV) (Szymczak et al. (2004) Nat. Biotechnol.22, 589-594) are used to separate genetic elements in a multicistronicvector. The efficacy of a particular multicistronic vector for use insynthesizing the desired recombinant retrovirus can readily be tested bydetecting expression of each of the genes using standard protocols.

Generation of the vector(s) can be accomplished using any suitablegenetic engineering techniques known in the art, including, withoutlimitation, the standard techniques of restriction endonucleasedigestion, ligation, transformation, plasmid purification, and DNAsequencing, for example as described in Sambrook et al. (MolecularCloning: A Laboratory Manual. Cold Spring Harbor Laboratory Press, N.Y.(1989)), Coffin et al. (Retroviruses. Cold Spring Harbor LaboratoryPress, N.Y. (1997)) and “RNA Viruses: A Practical Approach” (Alan J.Cann, Ed., Oxford University Press, (2000)).

The vector(s) may incorporate sequences from the genome of any knownorganism. The sequences may be incorporated in their native form or maybe modified in any way. For example, the sequences may compriseinsertions, deletions or substitutions.

Expression control elements that may be used for regulating theexpression of the components are known in the art and include, but arenot limited to, inducible promoters, constitutive promoters, secretionsignals, enhancers and other regulatory elements.

In one embodiment, a vector will include a prokaryotic replicon, i.e., aDNA sequence having the ability to direct autonomous replication andmaintenance of the recombinant DNA molecule extrachromosomally in aprokaryotic host cell, such as a bacterial host cell, transformedtherewith. Such replicons are well known in the art. In addition,vectors that include a prokaryotic replicon may also include a genewhose expression confers a detectable marker such as a drug resistance.Typical bacterial drug resistance genes are those that confer resistanceto ampicillin or tetracycline.

The vector(s) may include one or more genes for selectable markers thatare effective in a eukaryotic cell, such as a gene for a drug resistanceselection marker. This gene encodes a factor necessary for the survivalor growth of transformed host cells grown in a selective culture medium.Host cells not transformed with the vector containing the selection genewill not survive in the culture medium. Typical selection genes encodeproteins that confer resistance to antibiotics or other toxins, e.g.,ampicillin, neomycin, methotrexate, or tetracycline, complementauxotrophic deficiencies, or supply critical nutrients withheld from themedia. The selectable marker can optionally be present on a separateplasmid and introduced by co-transfection.

Vectors will usually contain a promoter that is recognized by thepackaging cell and that is operably linked to the polynucleotide(s)encoding the FM, affinity molecule, viral components, and the like. Apromoter is an expression control element formed by a DNA sequence thatpermits binding of RNA polymerase and transcription to occur. Promotersare untranslated sequences that are located upstream (5′) to the startcodon of a structural gene (generally within about 100 to 1000 bp) andcontrol the transcription and translation of the antigen-specificpolynucleotide sequence to which they are operably linked. Promoters maybe inducible or constitutive. Inducible promoters initiate increasedlevels of transcription from DNA under their control in response to somechange in culture conditions, such as a change in temperature.

One of skill in the art will be able to select an appropriate promoterbased on the specific circumstances. Many different promoters are wellknown in the art, as are methods for operably linking the promoter tothe gene to be expressed. Both native promoter sequences and manyheterologous promoters may be used to direct expression in the packagingcell and target cell. However, heterologous promoters are preferred, asthey generally permit greater transcription and higher yields of thedesired protein as compared to the native promoter.

The promoter may be obtained, for example, from the genomes of virusessuch as polyoma virus, fowlpox virus, adenovirus, bovine papillomavirus, avian sarcoma virus, cytomegalovirus, a retrovirus, hepatitis-Bvirus and Simian Virus 40 (SV40). The promoter may also be, for example,a heterologous mammalian promoter, e.g., the actin promoter or animmunoglobulin promoter, a heat-shock promoter, or the promoter normallyassociated with the native sequence, provided such promoters arecompatible with the target cell. In one embodiment, the promoter is thenaturally occurring viral promoter in a viral expression system.

Transcription may be increased by inserting an enhancer sequence intothe vector(s) Enhancers are typically cis-acting elements of DNA,usually about 10 to 300 bp in length, that act on a promoter to increaseits transcription. Many enhancer sequences are now known from mammaliangenes (globin, elastase, albumin, a-fetoprotein, and insulin).Preferably an enhancer from a eukaryotic cell virus will be used.Examples include the SV40 enhancer on the late side of the replicationorigin (bp 100-270), the cytomegalovirus early promoter enhancer, thepolyoma enhancer on the late side of the replication origin, andadenovirus enhancers. The enhancer may be spliced into the vector at aposition 5′ or 3′ to the antigen-specific polynucleotide sequence, butis preferably located at a site 5′ from the promoter.

Expression vectors will also contain sequences necessary for thetermination of transcription and for stabilizing the mRNA. Thesesequences are often found in the 5′ and, occasionally 3′, untranslatedregions of eukaryotic or viral DNAs or cDNAs and are well known in theart.

Plasmid vectors containing one or more of the components described aboveare readily constructed using standard techniques well known in the art.

For analysis to confirm correct sequences in plasmids constructed, theplasmid may be replicated in E. coli, purified, and analyzed byrestriction endonuclease digestion, and/or sequenced by conventionalmethods.

Vectors that provide for transient expression in mammalian cells mayalso be used. Transient expression involves the use of an expressionvector that is able to replicate efficiently in a host cell, such thatthe host cell accumulates many copies of the expression vector and, inturn, synthesizes high levels of a the polypeptide encoded by theantigen-specific polynucleotide in the expression vector. Sambrook etal., supra, pp. 16.17-16.22.

Other vectors and methods suitable for adaptation to the expression ofthe viral polypeptides are well known in the art and are readily adaptedto the specific circumstances.

Using the teachings provided herein, one of skill in the art willrecognize that the efficacy of a particular expression system can betested by transforming packaging cells with a vector comprising a geneencoding a reporter protein and measuring the expression using asuitable technique, for example, measuring fluorescence from a greenfluorescent protein conjugate. Suitable reporter genes are well known inthe art.

Transformation of packaging cells with vectors of the present inventionis accomplished by well-known methods, and the method to be used is notlimited in any way. A number of non-viral delivery systems are known inthe art, including for example, electroporation, lipid-based deliverysystems including liposomes, delivery of “naked” DNA, and delivery usingpolycyclodextrin compounds, such as those described in Schatzlein A G.2001. Non-Viral Vectors in Cancer Gene Therapy: Principles andProgresses. Anticancer Drugs. Cationic lipid or salt treatment methodsare typically employed, see, for example, Graham et al. Virol. 52:456,(1973); Wigler et al. Proc. Natl. Acad. Sci. USA 76:1373-76, (1979). Thecalcium phosphate precipitation method is preferred. However, othermethods for introducing the vector into cells may also be used,including nuclear microinjection and bacterial protoplast fusion.

Viral Vector and Packaging Cells

One of the vectors encodes the core virus (the “viral vector”). Thereare a large number of available viral vectors that are suitable for usewith the invention, including those identified for human gene therapyapplications, such as those described in Pfeifer A, Verma I M. 2001.Gene Therapy: promises and problems. Annu. Rev. Genomics Hum. Genet.2:177-211. Suitable viral vectors include vectors based on RNA viruses,such as retrovirus-derived vectors, e.g., Moloney murine leukemia virus(MLV)-derived vectors, and include more complex retrovirus-derivedvectors, e.g., lentivirus-derived vectors. Human Immunodeficiency virus(HIV-1)-derived vectors belong to this category. Other examples includelentivirus vectors derived from HIV-2, feline immunodeficiency virus(FIV), equine infectious anemia virus, simian immunodeficiency virus(SIV) and maedi/visna virus.

The viral vector preferably comprises one or more genes encodingcomponents of the recombinant virus as well as one or more genes ofinterest. The viral vector may also comprise genetic elements thatfacilitate expression of the gene of interest in a target cell, such aspromoter and enhancer sequences. In order to prevent replication in thetarget cell, endogenous viral genes required for replication may beremoved and provided separately in the packaging cell line.

In a preferred embodiment the viral vector comprises an intactretroviral 5′ LTR and a self-inactivating 3′ LTR.

Any method known in the art may be used to produce infectious retroviralparticles whose genome comprises an RNA copy of the viral vector. Tothis end, the viral vector (along with other vectors encoding the FM,affinity molecule, etc.) is preferably introduced into a packaging cellline that packages viral genomic RNA based on the viral vector intoviral particles.

The packaging cell line provides the viral proteins that are required intrans for the packaging of the viral genomic RNA into viral particles.The packaging cell line may be any cell line that is capable ofexpressing retroviral proteins. Preferred packaging cell lines include293 (ATCC CCL X), HeLa (ATCC CCL 2), D17 (ATCC CCL 183), MDCK (ATCC CCL34), BHK (ATCC CCL-10) and Cf2Th (ATCC CRL 1430). The packaging cellline may stably express the necessary viral proteins. Such a packagingcell line is described, for example, in U.S. Pat. No. 6,218,181.Alternatively a packaging cell line may be transiently transfected withplasmids comprising nucleic acid that encodes one or more necessaryviral proteins (along with the viral vector and the vectors encoding theFM and affinity molecules).

Viral particles comprising a polynucleotide with the gene of interestand an envelope comprising the FM and affinity molecules are collectedand allowed to infect the target cell. Target cell specificity may befurther improved by pseudotyping the virus. Methods for pseudotyping arewell known in the art.

In one embodiment, the recombinant retrovirus used to deliver the geneof interest is a modified lentivirus and the viral vector is based on alentivirus. As lentiviruses are able to infect both dividing andnon-dividing cells, in this embodiment it is not necessary for targetcells to be dividing (or to stimulate the target cells to divide).

In another embodiment the vector is based on the murine stem cell virus(MSCV). The MSCV vector provides long-term stable expression in targetcells, particularly hematopoietic precursor cells and theirdifferentiated progeny.

In another embodiment, the vector is based on a modified Moloney virus,for example a Moloney Murine Leukemia Virus. In a further embodiment,the vector is based on a Murine Stem Cell Virus (Hawley, R. G., et al.(1996) Proc. Natl. Acad. Sci. USA 93:10297-10302; Keller, G., et al.(1998) Blood 92:877-887; Hawley, R. G., et al. (1994) Gene Ther.1:136-138). The viral vector can also can be based on a hybrid virussuch as that described in Choi, J K; Hoanga, N; Vilardi, A M; Conrad, P;Emerson, S G; Gewirtz, A M. (2001) Stem Cells 19, No. 3, 236-246.

A DNA viral vector may be used, including, for example adenovirus-basedvectors and adeno-associated virus (AAV)-based vectors. Likewise,retroviral-adenoviral vectors also can be used with the methods of theinvention.

Other vectors also can be used for polynucleotide delivery includingvectors derived from herpes simplex viruses (HSVs), including ampliconvectors, replication-defective HSV and attenuated HSV (Krisky D M,Marconi P C, Oligino T J, Rouse R J, Fink D J, et al. 1998. Developmentof herpes simplex virus replication-defective multigene vectors forcombination gene therapy applications. Gene Ther. 5: 1517-30).

Other vectors that have recently been developed for gene therapy usescan also be used with the methods of the invention. Such vectors includethose derived from baculoviruses and alpha-viruses. (Jolly D J. 1999.Emerging viral vectors. pp 209-40 in Friedmann T, ed. 1999. Thedevelopment of human gene therapy. New York: Cold Spring Harbor Lab).

In the preferred embodiments the viral construct comprises sequencesfrom a lentivirus genome, such as the HIV genome or the SIV genome. Theviral construct preferably comprises sequences from the 5′ and 3′ LTRsof a lentivirus. More preferably the viral construct comprises the R andU5 sequences from the 5′ LTR of a lentivirus and an inactivated orself-inactivating 3′ LTR from a lentivirus. The LTR sequences may be LTRsequences from any lentivirus from any species. For example, they may beLTR sequences from HIV, SIV, FIV or BIV. Preferably the LTR sequencesare HIV LTR sequences.

The viral construct preferably comprises an inactivated orself-inactivating 3′ LTR. The 3′ LTR may be made self-inactivating byany method known in the art. In the preferred embodiment the U3 elementof the 3′ LTR contains a deletion of its enhancer sequence, preferablythe TATA box, Spl and NF-kappa B sites. As a result of theself-inactivating 3′ LTR, the provirus that is integrated into the hostcell genome will comprise an inactivated 5′ LTR.

Optionally, the U3 sequence from the lentiviral 5′ LTR may be replacedwith a promoter sequence in the viral construct. This may increase thetiter of virus recovered from the packaging cell line. An enhancersequence may also be included. Any enhancer/promoter combination thatincreases expression of the viral RNA genome in the packaging cell linemay be used. In a preferred embodiment the CMV enhancer/promotersequence is used.

The viral construct generally comprises a gene that encodes a protein(or other molecule, such as siRNA) that is desirably expressed in one ormore target cells. Preferably the gene of interest is located betweenthe 5′ LTR and 3′ LTR sequences. Further, the gene of interest ispreferably in a functional relationship with other genetic elements, forexample transcription regulatory sequences such as promoters and/orenhancers, to regulate expression of the gene of interest in aparticular manner once the gene is incorporated into the target cell. Incertain embodiments, the useful transcriptional regulatory sequences arethose that are highly regulated with respect to activity, bothtemporally and spatially.

Preferably the gene of interest is in a functional relationship withinternal promoter/enhancer regulatory sequences. An “internal”promoter/enhancer is one that is located between the 5′ LTR and the 3′LTR sequences in the viral construct and is operably linked to the genethat is desirably expressed.

The internal promoter/enhancer may be any promoter, enhancer orpromoter/enhancer combination known to increase expression of a genewith which it is in a functional relationship. A “functionalrelationship” and “operably linked” mean, without limitation, that thegene is in the correct location and orientation with respect to thepromoter and/or enhancer that expression of the gene will be affectedwhen the promoter and/or enhancer is contacted with the appropriatemolecules.

The internal promoter/enhancer is preferably selected based on thedesired expression pattern of the gene of interest and the specificproperties of known promoters/enhancers. Thus, the internal promoter maybe a constitutive promoter. Non-limiting examples of constitutivepromoters that may be used include the promoter for ubiquitin, CMV(Karasuyama et al J. Exp. Med. 169:13 (1989), beta-actin (Gunning et al.Proc. Natl. Acad. Sci. USA 84:4831-4835 (1987) and pgk (see, forexample, Adra et al. Gene 60:65-74 (1987), Singer-Sam et al. Gene32:409-417 (1984) and Dobson et al. Nucleic Acids Res. 10:2635-2637(1982)).

Alternatively, the promoter may be a tissue specific promoter. Severalnon-limiting examples of tissue specific promoters that may be usedinclude lck (see, for example, Garvin et al. Mol. Cell Biol. 8:3058-3064(1988) and Takadera et al. Mol. Cell Biol. 9:2173-2180 (1989)), myogenin(Yee et al. Genes and Development 7:1277-1289 (1993), and thy1(Gundersen et al. Gene 113:207-214 (1992). In addition, promoters may beselected to allow for inducible expression of the gene. A number ofsystems for inducible expression are known in the art, including thetetracycline responsive system and the lac operator-repressor system. Itis also contemplated that a combination of promoters may be used toobtain the desired expression of the gene of interest. The skilledartisan will be able to select a promoter based on the desiredexpression pattern of the gene in the organism and/or the target cell ofinterest.

In some embodiments the viral construct preferably comprises at leastone RNA Polymerase II or III promoters. The RNA Polymerase II or IIIpromoter is operably linked to the gene of interest and can also belinked to a termination sequence. In addition, more than one RNAPolymerase II or III promoters may be incorporated.

RNA polymerase II and III promoters are well known to one of skill inthe art. A suitable range of RNA polymerase III promoters can be found,for example, in Paule and White. Nucleic Acids Research., Vol 28, pp1283-1298 (2000), which is hereby incorporated by reference in itsentirety. The definition of RNA polymerase II or III promoters,respectively, also include any synthetic or engineered DNA fragment thatcan direct RNA polymerase II or III, respectively, to transcribe itsdownstream RNA coding sequences. Further, the RNA polymerase II or III(Pol II or III) promoter or promoters used as part of the viral vectorcan be inducible. Any suitable inducible Pol II or III promoter can beused with the methods of the invention. Particularly suited Pol II orIII promoters include the tetracycline responsive promoters provided inOhkawa and Taira Human Gene Therapy, Vol. 11, pp 577-585 (2000) and inMeissner et al. Nucleic Acids Research, Vol. 29, pp 16721682 (2001),which are incorporated herein by reference.

An internal enhancer may also be present in the viral construct toincrease expression of the gene of interest. For example the CMVenhancer (Karasuyama et al J. Exp. Med. 169:13 (1989) may be used incombination with the chicken .beta.-actin promoter. Again, one of skillin the art will be able to select the appropriate enhancer based on thedesired expression pattern.

The gene of interest is not limited in any way and includes any nucleicacid that the skilled practitioner desires to have integrated,transcribed, translated, and/or expressed in the target cell. Forexample, the gene of interest may encode a polypeptide, such as ahormone, toxin or antigen, or encode a nucleotide such as an siRNA.

In some embodiments, a gene of interest is incorporated as a safetymeasure and allows for the selective killing of infected target cellswithin a heterogeneous population, for example within an animal, such aswithin a human patient. In one such embodiment, the gene of interest isa thymidine kinase gene (TK), the expression of which renders a targetcell susceptible to the action of the drug gancyclovir.

In addition, more than one gene of interest may be placed in functionalrelationship with the internal promoter. For example a gene encoding amarker protein may be placed after the primary gene of interest to allowfor identification of cells that are expressing the desired protein. Inone embodiment a fluorescent marker protein, preferably greenfluorescent protein (GFP), is incorporated into the construct along withthe gene of interest. If one or more additional reporter genes isincluded, internal ribosomal entry site (IRES) sequences, or 2A elementsare also preferably included, separating the primary gene of interestfrom a reporter gene and/or any other gene of interest. The IRES or 2Asequences may facilitate the expression of the reporter gene, or othergenes.

The viral construct may also contain additional genetic elements. Thetypes of elements that may be included in the construct are not limitedin any way and will be chosen by the skilled practitioner to achieve aparticular result. For example, a signal that facilitates nuclear entryof the viral genome in the target cell may be included. An example ofsuch a signal is the HIV-1 flap signal.

Further, elements may be included that facilitate the characterizationof the provirus integration site in the target cell. For example, a tRNAamber suppressor sequence may be included in the construct.

In addition, the construct may contain one or more genetic elementsdesigned to enhance expression of the gene of interest. For example, awoodchuck hepatitis virus responsive element (WRE) may be placed intothe construct (Zufferey et al. J. Virol. 74:3668-3681 (1999); Deglon etal. Hum. Gene Ther. 11:179-190 (2000)).

A chicken .beta.-globin insulator may also be included in the viralconstruct. This element has been shown to reduce the chance of silencingthe integrated provirus in the target cell due to methylation andheterochromatinization effects. In addition, the insulator may shieldthe internal enhancer, promoter and exogenous gene from positive ornegative positional effects from surrounding DNA at the integration siteon the chromosome.

Any additional genetic elements are preferably inserted 3′ of the geneof interest.

In a specific embodiment, the viral vector comprises: a cytomegalovirus(CMV) enhancer/promoter sequence; the R and U5 sequences from the HIV 5′LTR; the HIV-1 flap signal; an internal enhancer; an internal promoter;a gene of interest; the woodchuck hepatitis virus responsive element; atRNA amber suppressor sequence; a U3 element with a deletion of itsenhancer sequence; the chicken beta-globin insulator; and the R and U5sequences of the 3′ HIV LTR.

The viral construct is preferably cloned into a plasmid that may betransfected into a packaging cell line. The preferred plasmid preferablycomprises sequences useful for replication of the plasmid in bacteria.

Delivery of the Virus

The virus may be delivered to the cell in any way that allows the virusto contact the target cells in which delivery of the gene of interest isdesired. In preferred embodiments, a suitable amount of virus isintroduced into an animal directly (in vivo), for example thoughinjection into the body. In one such embodiment, the viral particles areinjected into the animal's peripheral blood stream. Other injectionlocations also are suitable, such as directly into organs comprisingtarget cells. For example intracranial or intrahepatic injection may beused to deliver virus to the brain and liver respectively. Depending onthe particular circumstances and nature of the target cells,introduction can be carried out through other means including forexample, inhalation, or direct contact with epithelial tissues, forexample those in the eye, mouth or skin.

In other embodiments, target cells are preferably contacted with thevirus in vitro, such as in culture plates. The virus may be suspended inmedia and added to the wells of a culture plate, tube or othercontainer. The media containing the virus may be added prior to theplating of the cells or after the cells have been plated. Preferablycells are incubated in an appropriate amount of media to provideviability and to allow for suitable concentrations of virus in the mediasuch that infection of the host cell occurs.

The cells are preferably incubated with the virus for a sufficientamount of time to allow the virus to infect the cells. Preferably thecells are incubated with virus for at least 1 hour, more preferably atleast 5 hours and even more preferably at least 10 hours.

In both in vivo and in vitro delivery embodiments, any concentration ofvirus that is sufficient to infect the desired target cells may be used,as can be readily determined by the skilled artisan. When the targetcell is to be cultured, the concentration of the viral particles is atleast 1 pfu/μl, more preferably at least 10 pfu/μl, even more preferablyat least 400 pfu/μl and even more preferably at least 1×10⁴ pfu/μl.

In some embodiments, following infection with the virus in vitro, targetcells can be introduced into an animal. The location of introduction ofcultured cells will depend on the cell type used and the desired effect.For example, when the cells are hematopoietic cells, the cells can beintroduced into the peripheral blood stream. The cells introduced intoan animal are preferably cells derived from that animal, to avoid anadverse immune response. Cells also can be used that are derived from adonor animal having a similar immune makeup. Other cells also can beused, including those designed to avoid an immunogenic response.

The cells and animals incorporating target cells may be analyzed, forexample for integration, transcription and/or expression of the gene(s)of interest, the number of copies of the gene integrated, and thelocation of the integration. Such analysis may be carried out at anytime and may be carried out by any methods known in the art.

The methods of infecting cells disclosed above do not depend uponspecies-specific characteristics of the cells. As a result, they arereadily extended to all mammalian species. In some embodiments therecombinant virus is delivered to a human or to human cells. In otherembodiments it is delivered to an animal other than a human or non-humancells.

As discussed above, the modified retrovirus can be pseudotyped to conferupon it a broad host range. One of skill in the art would also be awareof appropriate internal promoters to achieve the desired expression of agene of interest in a particular animal species. Thus, one of skill inthe art will be able to modify the method of infecting cells derivedfrom any species.

Target Cells

A wide variety of cells may be targeted in order to deliver a gene ofinterest using a recombinant retrovirus as disclosed herein. The targetcells will generally be chosen based upon the gene of interest and thedesired effect.

In some embodiments, a gene of interest may be delivered to enable atarget cell to produce a protein that makes up for a deficiency in anorganism, such as an enzymatic deficiency, or immune deficiency, such asX-linked severe combined immunodeficiency. Thus, in some embodiments,cells that would normally produce the protein in the animal aretargeted. In other embodiments, cells in the area in which a proteinwould be most beneficial are targeted.

In other embodiments, a gene of interest, such as a gene encoding ansiRNA, may inhibit expression of a particular gene in a target cell. Thegene of interest may, for example, inhibit expression of a gene involvedin a pathogen life cycle. Thus cells susceptible to infection from thepathogen or infected with the pathogen may be targeted. In otherembodiments, a gene of interest may inhibit expression of a gene that isresponsible for production of a toxin in a target cell.

In other embodiments a gene of interest may encode a toxic protein thatkills cells in which it is expressed. In this case, tumor cells or otherunwanted cells may be targeted.

In still other embodiments a gene that encodes a protein to becollected, such as a therapeutic protein may be used and cells that areable to produce and secrete the protein are targeted.

Once a particular population of target cells is identified in whichexpression of a gene of interest is desired, a target molecule isselected that is specifically expressed on that population of targetcells. The target molecule may be expressed exclusively on thatpopulation of cells or to a greater extent on that population of cellsthan on other populations of cells. The more specific the expression,the more specifically gene delivery can be directed to the target cells.Depending on the context, the desired amount of specificity of themarker (and thus of the gene delivery) may vary. For example, forintroduction of a toxic gene, a high specificity is most preferred toavoid killing non-targeted cells. For expression of a protein forharvest, or expression of a secreted product where a global impact isdesired, less marker specificity may be needed.

As discussed above, the target molecule may be any molecule for which aspecific binding partner can be identified or created. Preferably thetarget molecule is a peptide or polypeptide, such as a receptor.However, in other embodiments the target molecule may be a carbohydrateor other molecule that can be recognized by a binding partner. If abinding partner for the target molecule is already known, it may be usedas the affinity molecule. However, if a binding molecule is not known,antibodies to the target molecule may be generated using standardprocedures. The antibodies can then be used as the affinity molecule, orto create an affinity molecule.

Thus, target cells may be chosen based on a variety of factors,including, for example, (1) the particular application (e.g., therapy,expression of a protein to be collected, and conferring diseaseresistance) and (2) expression of a marker with the desired amount ofspecificity.

Target cells are not limited in any way and include both germline cellsand cell lines and somatic cells and cell lines. Target cells can bestem cells derived from either origin. When the target cells aregermline cells, the target cells are preferably selected from the groupconsisting of single-cell embryos and embryonic stem cells (ES).

In one embodiment, target cells are CD20+ cell (see Examples 1-5). Someother non-limiting examples of target cells are CD34+ cells, CD4+ cells,dendritic cells, tumor cells and other dysfunctional cells, and cellsthat are susceptible to infection with a pathogen. Various affinitymolecules are available to target numerous cell types, for example,CD34+ cells, and dendritic cells, described in more detail below.

Depending on the vector that is to be used, target cell division may berequired for transformation. Target cells can be stimulated to divide invitro by any method known in the art. For example, hematopoietic stemcells can be cultured in the presence of one or more growth factors,such as IL-3, IL-6 and/or stem cell factor (SCF).

Although examples are discussed below in relation to the targeting CD34+stem cells and dendritic cells, one of skill in the art will be able toadapt the disclosure to other contexts.

Targeting of Lentiviral Vectors to Human CD34⁺ Hematopoietic Stem Cells

CD34 is a human hematopoietic stem cell (HSC) marker. HSCs may beprogrammed to differentiate into antigen-specific immune cells viavirus-mediated gene transfer. Targeted gene delivery into CD34⁺ HSCallows gene transfer in vivo, but could also be used in vitro.Therefore, a wide range of hematological disorders, such as variousanemias, leukemias, lymphomas, and platelet disorders may be treatedusing the disclosed methods and vectors to deliver the appropriatepolynucleotides to HSCs. Polynucleotides encoding proteins whoseexpression in HSCs would be beneficial to treatment of the varioushematological disorders will be apparent to the skilled artisan.

In some embodiments of the invention, CD34 is targeted. Various examplesof anti-CD34 antibodies are available and can be used as the basis of anaffinity molecule or as the affinity molecule if they are membraneassociated. For example, ATCC number HB-12346 is readily available fromthe ATCC and can be used to prepare an affinity molecule. Evaluation ofthe functional expression of anti-CD34 antibodies as the affinitymolecule on recombinant retrovirus may be accomplished using avirus-cell binding assay. TF-1 a, a human CD34+ cell line, may beobtained from the ATCC (ATCC number: CRL-2451) and used as a target cellfor such binding experiments. Transduction experiments may then beconducted in the TF-1 a line and primary human bone marrow or cord bloodcells. Transduction efficiency may be compared between variousantibodies, including natural and single chain forms. Once an efficientaffinity molecule is identified, it can be used in conjunction with anFM, such as SINmu or HAmu, to deliver a gene of interest to CD34+ cells,either in vivo or in vitro.

Targeting of Recombinant Virus to Dendritic Cells In Vivo

Dendritic cells (DCs) have been widely used to induce tumor-specifickiller (CD8) and helper (CD4) T cell responses in animal-tumor modelsand in cancer patients (Schuler et al. Curr. Top. Microbiol. 281,137-178 (2003)). Targeting of antigens and the induction of theirmaturation are part of an in situ DC vaccination approach. Thus,targeting lentiviral vectors to DCs in vivo using viruses as describedherein can be used therapeutically, for example, in treating melanomaand HIV. The DEC-205 endocytosis receptor is a preferred target surfaceantigen on the DC as DEC-205 is abundantly expressed on lymphoid tissueand can significantly improve the efficiency of antigen presentation.(Bonifaz, L. C. et al. J Exp. Med. 199, 815-824 (2004)). Anti-DEC-205antibody, preferably comprising the variable regions from an anti-DEC205antibody with the constant regions of IgG1) can be displayed on thesurface of a viral particle as the affinity molecule to directco-delivery of both a gene encoding an antigenic protein and amaturation stimulatory molecule, such as TNFα or CD40L, into DCs. Amaturation signal could also be delivered along with an antigen gene byusing anti-CD40 antibody as an affinity molecule.

As described in Example 6 below, recombinant lentiviruses have beencreated that co-display αmDEC-205 and SINmu to target bone marrowderived DCs in vitro. To target human DCs, membrane-bound antibodiesagainst human DCs, such as IgG₁ comprising the variable region from ahuman anti-DEC-205 antibody, are engineered into recombinant virusesDiseases such as HIV and melanoma can then be prevented and/or treatedby delivery of appropriate antigen genes to DCs using the recombinantvirus. In one embodiment, an anti-DEC-205 antibody comprising thevariable regions from a murine anti-DEC-205 antibody and the constantregions from human IgG₁ is used as an affinity molecule and SINmu isused as a fusogenic molecule (see Example 6) to target a recombinantlentivirus to DCs and deliver a gene encoding an antigen.

Transgenic Animals

The methods of the present invention can be used to create transgenicanimals. In some embodiments particular cells in an adult animal aretargeted to deliver a polynucleotide encoding a gene to be expressed inthose cells. In other embodiments an oocyte or one or more embryoniccells are infected with recombinant virus produced as described above.The virus delivers a polynucleotide encoding a gene of interest that isincorporated into the genome of the developing animal and can betransmitted from generation to generation. One of skill in the art willrecognize that the method of infection and the treatment of the cellfollowing infection will depend upon the type of animal from which thecell is obtained, and that the ability to target gene delivery toparticular cell types allows for in vivo or in vitro gene delivery.

Therapy

The methods of the present invention can be used to prevent or treat awide variety of diseases or disorders. Diseases or disorders that areamenable to treatment or prevention by the methods of the presentinvention include, without limitation, cancers, autoimmune diseases, andinfections, including viral, bacterial, fungal and parasitic infections.In some embodiments a disease is treated by using recombinantretroviruses to deliver a gene of interest to target cells, whereinexpression of the gene produces a protein or other molecule thataddresses a deficiency in the cell or in the animal as a whole.

In other embodiments, a gene is delivered to the target cell type thatregulates expression of a protein that is involved in the disease ordisorder. For example, a gene encoding an siRNA molecule may be providedto inhibit a gene involved in a pathogen life cycle, to reduce theexpression of a protein that is being overproduced, or to interfere witha pathway involved in the progression of the disease or disorder. Inother examples, genes are delivered that inhibit a particular cellularactivity by competing with a native molecule or that enhance a cellularactivity by acting synergistically or facilitating the activity of anative molecule.

In still other embodiments a gene is delivered that causes the death ofundesirable target cells, such as tumor cells. Alternatively a gene maybe delivered that prevents or reduces the ability of a tumor cell tomultiply.

Although illustrated in several particular contexts below, the skilledartisan will be able to adapt the methods and constructs disclosedherein in view of specific circumstances.

siRNAs

The methods described herein allow for vector-mediated delivery of RNAmolecules, and are particularly suited to the delivery to and expressionof small RNA molecules in target cells. According to some embodiments ofthe invention, an RNA molecule is delivered to a target cell, and thenexpressed within the target cell in order to down-regulate theexpression of a target gene. The ability to down-regulate a target genehas many therapeutic and research applications, including identifyingthe biological functions of particular genes. By delivering an RNAmolecule to a target cell and subsequently expressing the RNA moleculewithin the target cell, it is possible to knock-down (or down-regulate)the expression of any of a large number of genes, both in cell cultureand in mammalian organisms. In some embodiments genes that are necessaryfor the life cycle of a pathogen, such as a pathogenic virus, or thatare contributing directly or indirectly to a disease or disorder aredownregulated in a target cell with siRNA.

Thus, in some embodiments, the viral vector comprises an RNA expressioncassette encoding an siRNA molecule. An RNA expression cassette to bedelivered to a target cell preferably comprises a Pol III promoter andan RNA coding region. The RNA coding region preferably encodes an RNAmolecule that is capable of down-regulating the expression of aparticular gene or genes. The RNA molecule encoded can, for example, becomplementary to the sequence of an RNA molecule encoding a gene to bedown-regulated. In such an embodiment, the RNA molecule is designed toact through an antisense mechanism.

A preferred embodiment involves the delivery to a target cell andsubsequent expression of a double-stranded RNA complex, or an RNAmolecule having a stem-loop or a so-called “hairpin” structure. As usedherein, the term “RNA duplex” refers to the double stranded regions ofboth the RNA complex and the double-stranded region of the hairpin orstem-lop structure. An RNA coding region can encode a single strandedRNA, two or more complementary single stranded RNAs or a hairpin formingRNA.

Double stranded RNA has been shown to inhibit gene expression of geneshaving a complementary sequence through a process termed RNAinterference or suppression (see, for example, Hammond et al. Nat. Rev.Genet. 2:110-119 (2001)).

According to some embodiments of the invention, the RNA duplex or siRNAcorresponding to a region of a gene to be down-regulated is delivered toa target cell using the vectors described, and is then expressed in thetarget cell. The RNA duplex is substantially identical (typically atleast about 80% identical, and more typically at least about 90%identical) in sequence to the sequence of the gene targeted for downregulation. siRNA duplexes are described, for example, in Bummelkamp etal. Science 296:550-553 (2202), Caplen et al. Proc. Natl. Acad. Sci. USA98:9742-9747 (2001) and Paddison et al. Genes & Devel. 16:948-958(2002).

The RNA duplex to be delivered to the target cell is generally at leastabout 15 nucleotides in length and is preferably about 15 to about 30nucleotides in length. In some organisms, the RNA duplex can besignificantly longer. In a more preferred embodiment, the RNA duplex isbetween about 19 and 22 nucleotides in length. The RNA duplex is mostpreferably identical to the target nucleotide sequence over the duplexregion.

When the target cell gene to be down regulated is in a family of highlyconserved genes, the sequence of the duplex region can be chosen withthe aid of sequence comparison to target only the desired gene. If thereis sufficient identity among a family of homologous genes within anorganism, a duplex region can be designed that would down regulate aplurality of genes simultaneously.

The sequence of the RNA coding region, and thus the sequence of the RNAduplex to be delivered to the target cell, preferably is chosen to becomplementary to the sequence of a gene whose expression is to bedownregulated in a target cell. The degree of down regulation achievedwith a given RNA molecule for a given target gene will vary by sequence.One of skill in the art will be able to readily identify an effectivesequence. For example, in order to maximize the amount of suppression, anumber of sequences can be tested in cell culture prior to treatingtarget cells.

In some embodiments, the target (within the target cell) of the RNAduplex is a sequence that is necessary for the life cycle or replicationof a virus, including for example, gene expression of the virus and theexpression of a cellular receptor or co-receptor necessary for viralreplication. In one embodiment of the invention, the virus to beinhibited is the human immunodeficiency virus (HIV).

In some embodiments, the gene of interest to be delivered to the targetcell encodes at least one double stranded RNA having at least 90%homology and preferably identical to a region of at least about 15 to 25nucleotides in a nucleotide that is important for normal viralreplication. For example, the double stranded RNA may have homology to anucleic acid in a viral genome, a viral gene transcript or in a gene fora patient's target cellular receptor that is necessary for the lifecycle of the virus.

In some embodiments, siRNAs are delivered to treat infection such asHIV, Hepatitis A, B, C, D, E, or a wide range of other viral infections.One of skill in the art can target a cellular component, either an RNAor an RNA encoding a cellular protein necessary for a pathogen lifecycle, such as a viral life cycle. In a preferred embodiment, thecellular target chosen will not be a protein or RNA that is necessaryfor normal cell growth and viability. Suitable proteins for disruptingthe viral life cycle include, for example, cell surface receptorsinvolved in viral entry, including both primary receptors and secondaryreceptors, and transcription factors involved in the transcription of aviral genome, proteins involved in integration into a host chromosome,and proteins involved in translational or other regulation of viral geneexpression.

A wide variety of molecules are specifically associated with pathogensand can be targeted by the methods disclosed herein. These include anumber of cellular proteins that are known to be receptors for viralentry into cells (Baranowski, et al. Science 292: 11021105). Somecellular receptors that are involved in recognition by viruses arelisted below: Adenoviruses: CAR, Integrins, MHC I, Heparan sulfateglycoaminoglycan, Siliac Acid; Cytomegalovirus: Heparan sulfateglycoaminoglycan; Cox sackieviruses: Integrins, ICAM-1, CAR, MHC I;Hepatitis A: murine-like class I integral membrane clycoprotein;Hepatitis C: CD81, Low density lipoprotein receptor; HIV (Retroviridae):CD4, CXCR4, Heparan sulfate glycoaminoglycan; HSV: Heparan sulfateglycoaminoglycan, PVR, HveB, HveC; Influenza Virus: Sialic acid;Measles: CD46, CD55; Poliovirus: PVR, HveB, HveC; Human papillomavirus:Integrins. One of skill in the art will recognize that the invention isnot limited to use with receptors (or other molecules) that arecurrently known. As new cellular receptors and coreceptors arediscovered, the methods of the invention can be applied to suchsequences.

In some embodiments of the invention, HIV is particularly targeted andthe retroviral construct comprises an RNA coding region that encodes adouble stranded molecule having at least 90% homology to the HIV viralRNA genome, an expressed region of the HIV viral genome (for example, toany region of about 19-25 nucleotides in length of the 9-kb transcriptof the integrated HIV virus), or any of the variously spliced mRNAtranscripts of HIV (Schwartz et al. J. Virol. 1990; 64(6): 2519-29).Target regions within the HIV transcripts can be chosen to correspond toany of the viral genes, including, for example, HIV-1 LTR, vif, nef, andrev. In other embodiments, the RNA coding region encodes a doublestranded region having at least 90% homology to a receptor orco-receptor of the HIV virus. For example, the primary receptor for HIVentry into T cells is CD4. In a preferred embodiment, the co-receptorsCXC chemokine receptor 4 (CXCR4) and CC chemokine receptor 5 (CCR5) aredown-regulated according to the methods of the invention. CXCR4(Feddersppiel et al. Genomics 16:707-712 (1993)) is the majorco-receptor for T cell trophic strains of HIV while CCR5 (Mummidi et al.J. Biol. Chem. 272:30662-30671 (1997)) is the major co-receptor formacrophage trophic strains of HIV. Other cellular targets against HIVinclude the RNA transcripts for proteins involved in the HIV life cycle,including cyclophilin, CRM-1, importin-β, HP68 (Zimmerman C, et al.Identification of a host protein essential for assembly of immatureHIV-1 capsids. Nature 415 (6867): 88-92 (2002)) and other as yet unknowncellular factors.

In one particular embodiment, a recombinant retrovirus is used tointroduce siRNAs against the HIV-1 co-receptor CCR5 into humanperipheral blood T cells. Reducing CCR5 expression by siRNAs providesprotection from CCR5-tropic HIV-1 viral infection (Qin et al. (2003).Proc. Natl. Acad. Sci. 100, 183-188). Targeted delivery of such siRNAsto human CD34⁺ cells may thus reconstitute CD4+ cells that are resistantto HIV-1 infection. Recombinant lentiviruses comprising an affinitymolecule that targets CD34, such as an anti-CD 34 antibody, a fusogenicmolecule such as SIN or HA, and encoding CCR5-siRNA and, optionally, GFPmay be injected intravenously to treat HIV.

Vaccination

As discussed above, various cell-specific binding determinants tosurface dendritic cell markers are contemplated for use in producingrecombinant retrovirus that delivers a gene encoding an antigen to DCs.For example, a hybridoma cell line for human anti-DEC-205 antibody(αhDEC-205) is available from the ATCC (ATCC number: CRL-2460). A geneencoding an antigen against which an immune response is desired, such asfor cancer (for example, Mart-1), or another disease/disorder (such asviral infection) may be delivered to DCs using the methods describedabove. The gene for the antigen may be accompanied by genes encodingstimulatory molecules, such as TNFα/CD40L, and/or a reporter molecule,such as GFP using multiple vectors or, preferably, a multicistronicvector system.

In some embodiments of the invention, human DCs are generated fromCD34a+ human hematopoietic progenitors using an in vitro culture method(e.g., Banchereau et al. Cell 106, 271-274 (2001)). ahDEC-205 andS1Nmu-bearing viruses are generated comprising a gene encoding anantigen against which an immune response is desired and are used totransduce human DCs. Transduction specificity and efficiency may bequantified by FACS. Maturation of DCs can be characterized by FACSanalysis of up-regulation of surface marker such as MHC II.

In other embodiments, virus may be injected in vivo, where it contactsnatural DCs and delivers the gene encoding the antigen. At selectedintervals, DCs from the recipient's lymphoid organs may be used tomeasure expression, for example, by observing marker expression, such asGFP. T cells from lymph nodes and spleens of virus-treated recipientsmay be measured from the magnitude and durability of response to antigenstimulation. Tissue cells other than DCs, such as epithelial cells andlymphoid cells, may be analyzed for the specificity of in vivo genedelivery.

It is widely agreed that the most effective potential method to end theAIDS epidemic (and other viral diseases) is a vaccine. Unfortunately, todate no vaccination method against HIV has successfully passed a phaseIII trial. Thus, there is an urgent need for novel and effectivevaccination strategies. In some embodiments of the invention DCvaccination is used. A gene is cloned encoding a viral protein, such asthose described above, into a viral vector. Patients are infected withviruses comprising an affinity molecule that targets DCs, such asαhDEC-205 by injection. In an animal model, molecularly cloned HIVreporter viruses (NFNSZ-r-HSAS, NL-r-HSAS) and clinical isolates may beused to challenge the animals by tail vein injection. Evidence ofinfection may be monitored over time in splenocytes, lymph nodes, andperipheral blood. PCR for HIV-gag protein and FACS for HAS in thereporter viruses may be used to test for viral integration andreplication. Productive in situ DC vaccination may increase resistanceto a HIV challenge.

Treatment of Tumors and Other Abnormal Cells

In other embodiments, the disclosed method can be used to treat tumorsor other abnormal cell growth. Tumor associated antigens are known for avariety of cancers including, for example, prostate cancer and breastcancer. In some breast cancers, for example, the Her-2 receptor isoverexpressed on the surface of cancerous cells. A number of tumorassociated antigens have been reviewed (see, for example, Boon T,Cerottini J C, Vandeneynde B, Vanderbruggen P, Vanpel A, Annual ReviewOf Immunology 12: 337-365, 1994; Renkvist N, Castelli C, Robbins P F,Parmiani G. Cancer Immunology Immunotherapy 50: (1) 3-15 Mar. 2001).Thus, in some embodiments an antibody to a known tumor associatedantigen is used to prepare an affinity molecule.

In other embodiments, an antigen related to a disease or disorder isidentified from the patient to be treated. For example, an antigenassociated with a tumor may be identified from the tumor itself by anymethod known in the art.

Antibodies to tumor associated antigens may be displayed on a viralsurface to target delivery of genes of interest into tumor cells. Thegenes of interest may encode a toxin whose expression kills the targettumor cells. In some embodiments the expression of the toxin isinducible. In other embodiments the gene of interest may interfere withthe cell cycle and reduce or eliminate the ability of the cell todivide.

These methods may be adapted to treat a wide range of diseases byselecting a particular target molecule on a pathologic cell of interestand synthesizing an affinity molecule to that particular targetmolecule. Next, a recombinant retrovirus with the membrane boundaffinity molecule and a fusogenic molecule is assembled to deliver thegene of interest into the target cell.

In some embodiments, a recombinant retrovirus may be used to target anon-Hodgkin's lymphoma cell. A HSV thymidine kinase (HSV-tk) suicidegene and a GFP reporter gene may be delivered into tumor cells; thesetwo genes may be linked by an internal ribosome entry site (IRES) toaccomplish co-expression.

In some embodiments, a retrovirus as described herein may be used totarget a tumor cell with a specific cell surface antigen, such as abreast cancer tumor cell. A hybridoma cell line for anti-human Her2antibody is available from the ATCC (ATCC number: CRL: 1043). Virusesbearing such antibodies may be used to target and kill cancer cells.

Treatment of X-Linked Severe Combined Deficiency

Genetic defects in the common γ chain (γ_(c)) result in the X-linkedsevere combined immunodeficiency disease (X-SCID) in humans. Withouttreatment, X-SCID patients suffer from severe infections, failure tothrive, and usually die within the first year of life. It is commonlyagreed that the ultimate therapeutic treatment for this disease is genetherapy. A retrovirus as disclosed may be used to deliver the commonγ_(c) gene into purified CD34⁺ hematopoietic stem cells (HSCs) in vitroand transfer back γ_(c)-transduced HSCs to patients to reconstitute theimmune system. In other embodiments, the recombinant virus is providedin vivo and targets CD34+ stem cells to treat X-SCID. SCF can be used tospecifically target the recombinant retrovirus to the target cells,where the γ_(c) gene is delivered.

In one embodiment patients suffering from X-SCID are treated. The fulllength of γ_(c) cDNA is amplified and cloned into a lentiviral vector asdescribed above. Packaging cells, such as 293 cells are transfected withthe lentiviral vector, as well as one or more vectors encoding anaffinity molecule and a fusogenic molecule. The viruses bearing SCF, oranother affinity molecule targeting HSCs and a fusogenic molecule, suchas SINmu, are collected and concentrated. The γ_(c)-deficient patientsare administered the viruses by injection. Testing with and withoutmobilization may be performed to relocate HSCs to circulating blood.Peripheral lymphoid cells may then be analyzed for 6-8 weeks to detectthe existence of mature T and B cells.

Antigen-Specific Immune Cell Therapy

In other embodiments recombinant retrovirus is used to deliverpolynucleotides encoding immune cell receptors, such as T Cell receptorsor B cell receptors, to human stem cells. The stem cells then developinto mature immune cells, such as T cells or B cells, with theirspecificity determined by the receptor with which they were transduced.In one embodiment, a patient that is suffering from a disease ordisorder is treated by generating immune cells with a desiredspecificity using this approach. An antigen may be previously known tobe associated with the disease or disorder, or may be identified by anymethod known in the art. For example, an antigen to a type of cancerfrom which a patient is suffering may be known, such as a tumorassociated antigen. Tumor associated antigens are not limited in any wayand include, for example, antigens that are identified on cancerouscells from the patient to be treated.

Once an antigen has been identified and/or selected, one or more T cellreceptors that are specific for the antigen are then identified. If a Tcell receptor specific for the identified disease-associated antigen isnot already known, it may be identified by any method known in the art.T cell receptors may be identified from cytotoxic T cells, from helper Tcells, or both, depending on the type of immune cell that is to begenerated in the patient. For example, if cytotoxic T cells are to begenerated in the patient, the T cell receptor is identified from a CTL.On the other hand, if helper T cells are to be generated, the T cellreceptor is identified from a helper T cell. As discussed below, in someembodiments a T cell receptor from a CTL and a T cell receptor from ahelper T cell are both utilized.

A polynucleotide that encodes the desired T cell receptor is identified.Preferably the polynucleotide comprises a cDNA that encodes the T cellreceptor α subunit and a cDNA that encodes the T cell receptor βsubunit. The polynucleotides encoding the T cell receptor are preferablyintroduced into target cells (preferably hematopoietic stem cells) usinga modified retrovirus, more preferably a modified lentivirus, includinga fusion molecule and cell-specific binding determinant as describedabove. The virus first binds to the target cell membrane by way of themembrane-bound affinity molecule, and the polynucleotides encoding the Tcell receptor subunits enter the cytosol by action of the fusionmolecule. The gene of interest (e.g., one encoding the T cell receptor)is then preferably integrated into the cell's genome and expressed. Ifcontacted ex vivo, the target cells are then transferred back to thepatient, for example by injection, where they develop into immune cellsthat are capable of generating an immune response when contacted withthe identified antigen. However, in preferred embodiments the virus isinjected into the patient where it specifically transduces the targetedcells. The resulting immune cells generated in the patient express theparticular TCR and the patient is able to mount an effective immuneresponse against the disease or disorder.

In some embodiments the T cell receptor is cloned from cytotoxic Tcells. This results in the generation of cytotoxic T cells in thepatient. In other embodiments the T cell receptor is cloned from ahelper T cell, resulting in the generation of helper T cells in thepatient.

In still other embodiments B cells are generated in the patient bydelivering polynucleotides encoding B cell receptors to the targetcells. The population of target cells is divided and some stem cells aretransfected with a vector encoding a T cell receptor obtained from acytotoxic T cell and some stem cells are transfected with a vectorencoding a T cell receptor obtained from a helper T cell. The targetstem cells are transferred into the patient, resulting in thesimultaneous generation of a population of helper T cells specific forthe disease or disorder and a population of cytotoxic T cells specificfor the disease or disorder in the patient.

The following examples are offered for illustrative purposes only, andare not intended to limit the scope of the present invention in any way.Indeed, various modifications of the invention in addition to thoseshown and described herein will become apparent to those skilled in theart from the foregoing description and fall within the scope of theappended claims.

All patent and literature references cited in the present specificationare hereby incorporated by reference in their entirety.

Experimental Methods

The following experimental methods were used in Examples 1-5 below.

Construct Preparation

The cDNAs of the light and heavy chain constant regions of the membranebound human IgG₁ were amplified and inserted downstream of human CMV andEF1α promoters, respectively, of the pBudCE4.1 vector (Invitrogene).(See FIG. 13a ) The light and heavy chain variable regions form themurine anti-CD20 antibody (clone 2H7) were then cloned using PCRamplification and inserted directly upstream of the correspondingconstant regions. The resulting construct was designated as pαCD20. (SeeFIG. 13b ) cDNAs of human Igα and Igβ were also cloned into a pBudCE4.1vector (Invitrogene) to yield pIgαβ.

The construct encoding HAmu was provided by the laboratory of Dr. Cannonat the University of Southern California (A. H. Lin et al., Hum. Gene.Ther. 12, 323 (2001)). The cDNA for wild-type SIN was obtained from Dr.Strauss's laboratory at Caltech. PCR mutagenesis and assembly were usedto generate the mutant SIN as described in Morizono et al., Nature Med.11, 346 (2005), except that a 10 amino acid residue tag sequencereplaced the ZZ domain of protein A, which is located between amino acid71 and 74 of the E2 glycoprotein of SIN. This version of SIN isdesignated as SINmu.

Virus Production

Lentivirus were generated by transfecting 293T cells using a standardcalcium phosphate precipitation technique. 293T cells (−80% confluent)in 6-cm culture dishes were transfected with the appropriate lentiviralvector plasmid (5 μg), together with 2.5 μg each of pαCD20, pIgαβ, andthe package vector plasmids (pMDLg/pRRE and pRSV-Rev) (Sandrin et al.Curr. Top. Microbio. Immunol. 281:137 (2003)). The viral supernatantswere harvested 48 and 72 hours after transfection and filtered through a0.45-μm pore size filter.

To prepare high titer lentivirus, the viral supernatants wereconcentrated using ultracentrifugation (Optima L-80 K preparativeultracentrifuge, Beckman Coulter) for 90 min at 50,000×g. Particles werethen resuspended in an appropriate volume of cold PBS.

Cell Line Construction

The 293T/CD20 cell line was generated by stable transduction viaVSVG-pseudotyped lentivirus. The cDNA of human CD20 was cloneddownstream of the human ubiquitin-C promoter in the plasmid FUW (FUGWwithout GFP; Lois et al. Science 295:868-872 (2002)) to generateFUW-CD20. The lentiviral vector FUW-CD20 was then pseudotyped with VsVgand was used to transduce 293T. The resulting cells were subjected tocell sorting to obtain a uniform population of CD20⁺ cells designated as293T/CD20.

Virus-Cell Binding Assay

Cells (293T/CD20 or 293T, 0.1×10⁶) were incubated with 500 μL of viralsupernatant at 4° C. for half an hour and washed with 4 ml of cold PBS.The cells were then stained with the following three antibodies: ananti-human IgG antibody (BD Pharmingen) to stain αCD20, an anti-humanCD20 antibody (BD Pharmingen) to stain CD20, and an anti-FPV HApolyclonal antibody (obtained from H.-D. Klenck, Institute of Virology;Philipps-University, Marburg, Germany) to stain HAmu, or an anti-tagantibody (Roche) to stain SINmu. After staining, cells were analyzed byfluorescence-activated cell sorting (FACS.

Targeted Transduction of 293T/CD20 Cells In Vitro

293T/CD20 cells (0.2×10⁶/well) or 293T cells (0.2×10⁶/well) were platedin a 24-well culture dish, and spin-infected with viral supernatants(0.5 ml/well) at 2,500 rpm, 30° C. for 90 min. using a Beckman Allegra6R centrifuge. Then the medium was removed and replaced with freshmedium and incubated for a further 3 days at 37° C. with 5% CO₂. Thepercentage of GFP cells was determined by FACS. The transduction titerwas measured at the dilution ranges that exhibited a linear response.

Effects of Soluble Antibody and NH4Cl on Viral Transduction

293T/CD20 cells (0.2×10⁶) and 0.5 mL of viral supernatants wereincubated for 8 hours in the absence or presence of a gradient dose ofanti-human CD20 antibody (BD Pharmingen) or NH₄Cl. The medium wasreplaced with fresh medium and incubated for another 2 days at 37° C.with 5% CO₂. FACS analysis was used to quantify transduction efficiency.

Cell-Cell Fusion Assay

293T cells (0.1×10⁶) transiently transfected to express GFP and surfacecsCD20 and fusion protein (either HAmu or S1Nmu), and 293T/CD20 cells(0.1×10⁶) were mixed together, washed twice with normal PBS (pH=7.4),and incubated in 1500 low pH PBS (pH-5.0) or normal pH PBS (pH=7.4) (asa control) for half an hour at 37° C. with 5% CO₂. The cells were thenwashed extensively and cultured in the regular medium for one day. Cellswere visualized by an epifluorescence microscope equipped with a GFPfilter set. Targeted transduction of primary human B cells in vitro

Fresh, un-fractionated human peripheral blood mononuclear cells (PBMCs)(2×10⁶) (AllCells, LLC) were incubated with concentrated virus withtotal transduction units (TU) of 10×10⁶ (based on the titer on 293T/CD20cells). LPS (50 μg/mL) was then added for B cells to survive and grow.After two days, cells were harvested and washed in PBS. B cellpopulation was determined by FACS staining using anti-human CD20 andCD19 antibodies. Targeting transduction was quantified by gating on thedifferent populations of cells and measuring their GFP expression.

Targeted Transduction of Primary Human B Cells In Vivo

RAG^(−/−−/−)female mice (Taconic) of 6-8 weeks old were given 360 radswhole body irradiation. On the following day, 100×10⁶ fresh human PBMCs(AllCells, LLC) were transferred by tail vein injection into each mouse.After six hours, concentrated viruses (100×10⁶ TU/mouse) or PBS (ascontrol) were administered into these mice via the tail vein. Two dayslater, whole blood was collected from these mice via heart puncture andthe cells were stained for human CD3 and CD20 and then analyzed by FACSfor CD3, CD20 and GFP expression. The mice were maintained on the mixedantibiotic sulfmethoxazole and trimethoprim oral suspension (Hi-TechPharmacal) in a sterile environment in the California Institute ofTechnology animal facility in accordance with institute regulations.

Example 1 Targeted Cell Transduction Utilizing Retroviral Vectors FUGW/αCD20+HAmu and FUGW/α CD20+SINmu

One antibody chosen to serve as the basis of an affinity molecule,according to some embodiments of the invention, is the anti-CD20antibody (α CD20), a version of which is currently being used in thetreatment of B-cell lymphomas. Physiologically, CD20 is expressed at thepre-B-cell stage of development and throughout B-cell maturation;hematopoietic stem cells do not express CD20. When B-cells mature intoplasma cells, expression of CD20 is diminished. Thus, CD 20 representsan ideal target for therapy of, for example, B-cell lymphomas andleukemia. A construct that encodes a mouse/human chimeric anti-CD20antibody with the human membrane-bound IgG constant region (pαCD20) wasgenerated as described above. Genes encoding human Igα and Igβ, the twoassociated proteins that are required for surface expression ofantibodies, were cloned into a construct designated pIgαβ (FIG. 1).

The production of lentiviruses enveloped with both anti-CD20 antibodyand candidate fusion molecules (FMs) was achieved by co-transfection of293T cells with the lentiviral vector FUGW (Lois et al. Science295:868-872 (2002)), plasmids encoding viral gag, pol, and rev genes,pαCD20, pIgαβ and pFM (the plasmid encoding a FM, either HAmu or SINmu),using a standard calcium phosphate precipitation method. FUGW is aself-inactivating and replication-incompetent lentiviral vector whichcarries the human ubiquitin-C promoter driving the GFP reporter gene (C.Lois, E. J. Hong, S. Pease, E. J. Brown, D. Baltimore, Science 295, 868(2002)). (See FIG. 14) As a control, the envelope glycoprotein derivedfrom vesicular stomatitis virus (VSVG) was used as recognition andfusion protein.

FACS analysis of the transfected cells showed that virtually allexpressed some level of GFP as an indicator of the presence of the viralvector (FIGS. 3B and 3D, upper panels). Some 30% of GFP-positive cellsco-expressed HAmu and αCD20 on the cell surface (FIG. 3B, lower panel).A slightly smaller percentage (−20%) of the 293T cells exhibitedco-expression of GFP, SINmu, and αCD20 (FIG. 3D). The resultant virusesfrom these transfected production cells were designated FUGW/αCD20+HAmuand FUGW/αCD20+SINmu.

To examine whether αCD20 and the FM were incorporated in the samevirion, a virus-cell binding assay was performed. As a target, a 293Tcell line was made stably expressing the CD20 protein antigen, asdescribed above (293T/CD20, FIG. 4A). The parental cell line 293T servedas a negative control. The viral supernatants were incubated with thetarget cells at LIC for half an hour. The resultant binding was assayedvia a three-staining scheme (FIG. 4B). FACS analysis showed thatrecombinant lentivirus bearing αCD20 was in fact able to bind to CD20expressing 293T cells (FIG. 4C, upper panels). The control of 293T cellswith no CD20 expression displayed no detectable ccCD20, showing that thevirus binding to cells must be due to a specific interaction between thecell surface CD20 antigen and the viral surface αCD20 molecule. Inanother control, the virus bearing only FM exhibited no ability to bindboth cells, indicating that the HAmu and SINmu did lack the capacity forcell binding. FACS analysis also showed that the virus bound to the293T/CD20 cell surface displayed the FMs (FIG. 4C, lower panels),suggesting that both αCD20 and FM were incorporated on the same virion,which was further confirmed by FACS plots of αCD20 versus FM (FIG. 4D).In addition to co-display, these results indicate that the presence ofthe FM does not affect the αCD20 binding to CD20.

To confirm that αCD20 was functionally displayed on the lentiviralsurface, a virus-cell binding assay was performed. 293T cells wereengineered to over-express CD20. The human CD20 was cloned and itsexpression on 293T cells was confirmed by FACS staining. 293T cellsstably expressing CD20 antigen were sorted out as target cells(designated as 293T/CD20). Viral supernatants were incubated with293T/CD20 cells at 4° C. for 1 hr; 293T were included as controls.Binding activity was measured by FACS staining using the antibodyagainst the constant region of αCD20 (human IgG C region); cells werealso co-stained with the antibody against the surface antigen CD20. Asshown in FIG. 17, our binding assay revealed that lentivirusesdisplaying αCD20 (FUGW/αCD20+HAmu and FUGW/αCD20+SINmu) were able tospecifically bin to CD20⁺ cells, suggesting αCD20 was indeedfunctionally incorporated onto the viral surface. FACS plots alsoindicated the down-regulation of CD20 on the 293T surface upon virusbinding.

Example 2 Transduction of CD20-Expressing Target Cells and 293T CellsUtilizing the Retroviral Vector FUGW/αCD20+HAmu and FUGW/αCD20+SINmu

Next, the efficacy of a αCD20-bearing virus in transferring genes intocells expressing CD20 in a cell-specific manner was tested. GFPexpression was used to measure the transduction efficiency. Thesupernatants containing virus bearing various surface proteins wereincubated with CD20-expressing target cells and 293T cells served as acontrol. Four days post-transduction, the efficiency of targeting wasanalyzed by FACS. FIG. 5A (rightmost panel) shows that FUGW/αCD20+HAmuviral particles could specifically transduce 16% of 293T/CD20 cells.Panels to the left show that transduction required the presence on thevirions of HAmu, but there was some background transduction with virionslacking αCD20, likely due to residual weak binding of HAmu to itsligand, sialic acid. The titer for FUGW/αCD20+HAmu (fresh viralsupernatant, no concentration) was estimated to be—1×10⁵ transductionunits (TU)/mL. The titer was determined by the percentage of GFP cellsin the dilution ranges that showed a linear response. The 293T cellsshowed a small background infection level but no specific transductionby FUGW/αCD20+Hamu (FIG. 5A, lower panels).

When SINmu was used as the fusion protein, substantial enhancement ofspecific transduction was observed (52%, FIG. 5B). The titer forFUGW/αCD20+SINmu was estimated to be—1×10⁶ TU/mL. Also, a much lowertransduction was detected in the absence of the binding protein (−1%).Thus the data in FIG. 5B shows that SINmu is a preferred fusion proteinto partner with αCD20 for targeting the virus. When the transduction wasmonitored at various time points using FACS, it was found thatSINmu-containing virions exhibited faster transduction kinetics thanthose with HAmu. Both FUGW/αCD20+HAmu and FUGW/αCD20+SINmu could beconcentrated by ultracentrifugation with a >90% recovery rate, which isimportant for in vivo applications.

To assess whether αCD20 and the fusion protein (HAmu or SINmu) had to beincorporated into the same viral particle, and therefore functioned incis to mediate transduction, Virus generated from FUGW/αCD20 was mixedwith virus generated from FUGW/HAmu or FUGW/SINmu, each displaying onlyone protein, and their transduction of 293T/CD20 cells was tested. Thisprocedure did not result in specific transduction, indicating that thespecific transduction conferred by the engineered recombinant virusesrequires that the two proteins be displayed on the same viral particle.

Thus, two distinct proteins can contribute to the binding and fusionevents of engineered lentiviruses for targeted transduction. To furtherconfirm that the specificity observed was a consequence of interactionbetween αCD20 and CD20, 293T/CD20 cells were transduced in the presenceof anti-CD20 blocking antibody. As expected, a dramatic decrease ofinfectivity was detected for both FUGW/αCD20+HAmu and FUGW/αCD20+SINmuvirus (FIG. 5D), indictating that antibody-antigen binding facilitatestargeted transduction.

To examine the requirement for a low pH compartment to allow therecombinant lentivirus to penetrate into cells, both FUGW/αCD20+HAmu andFUGW/αCD20+SINmu virus was incubated with 293T/CD20 cells in the absenceor presence of ammonium chloride (NH₄Cl), which neutralizes acidicendosomal compartments. Addition of NH₄Cl to cells completely abolishedtransduction by either FUGW/αCD20+HAmu virus (not shown) orFUGW/αCD20+SINmu (FIG. 5E). These results are consistent with the low pHrequirement of hemagglutinin and Sindbis virus glycoprotein to triggermembrane fusion.

More direct evidence for pH dependent fusion was provided by a cell-cellfusion assay. 293T cells expressing GFP and surface αCD20 and FM wereincubated with 293T/CD20 cells in a low-pH buffer for half an hour,followed by culturing in regular medium. Both HAmu and SINmu inducedcell-cell fusion by forming multi-nucleated polykaryons (FIG. 5C). Theinteraction between αCD20 and CD20 dramatically enhances the probabilityof fusion, because a similar experiment with cells that lacked αCD20 andCD20 yielded a much lower level of fusion. The αCD20/CD20 interactionbrings the cell membranes into close approximation, facilitating theaction of the fusion protein.

Example 3 Transduction of Primary Human B-Lymphoid Cells Using theRetroviral Vector FUGW/αCD20+SINmu

Having established the ability of the system to mediate CD20-specifictransduction of artificially created cell lines, the specifictransduction of primary human B-lymphoid cells, cells that naturallycarry the CD20 antigen, was investigated. Fresh, unfractionated humanperipheral blood mononuclear cells (PBMCs) were transduced withFUGW/αCD20+SINmu and then stimulated with lipopolysaccharide (LPS) toexpand the B cell population. Four days later, the cells were stainedfor CD19 (a B cell marker), CD20 and GFP expression (FIG. 6A). Over 35%of cells were CD20⁺ B cells under the described culture condition. Themajority of them were GFP^(±). On the contrary, virtually no GFP cellswere detected among CD20⁻ non-B cells, confirming that the transductionwas strictly dependent on CD20 expression. In another controlexperiment, fresh PBMCs were transduced with FUGW/αCD20+SINmu followedby stimulation with phorbol-12-myristate-13-acetate (PMA) and ionomycinto expand T cells. FACS analysis of these T cells showed no expressionof GFP (FIG. 7), confirming transduction specificity.

Example 4 Demonstration of Transduction Utilizing Lentiviral VectorsCCMV/αCD20+SINmu and CPGK/αCD20+SINmu

To demonstrate that the targeting method is not limited to thelentiviral vector FUGW, two additional lentiviral vectors with differentpromoter configurations were evaluated. Kohn et al. have incorporatedthe immunoglobulin heavy chain enhancer (Eμ) with associated matrixattachment regions into lentivectors carrying either the humancytomegalovirus (CMV) promoter (CCMV) or the murine phosphoglyceratekinase promoter (CPGK) (C. Lutzko et al. J. Virol. 77, 7341-51 (2003)).These two lentiviral vectors were then adapted into the system andrecombinant lentiviruses CCMV/αCD20+SINmu and CPGK/αCD20+SINmu wereprepared. Transduction of PBMC-derived B cells with these viralsupernatants exhibited results similar to those observed previously withFUGW (FIG. 6A). Stable integration of the GFP-transgene was detected bygenomic PCR amplification (FIG. 6B).

Example 5 Testing of In Vivo Efficacy of Lentiviral Vectors in MediatingSpecific Transduction

Next, the efficacy of the system in mediating specific transduction invivo was tested. For this purpose, a human PBMC xenografted mouse modelwas used. Fresh human PBMCs (100×10⁶/mouse) were transferred intoirradiated immunodeficient RAG2^(−/−)γ_(c) ⁻/− mice through a tail veininjection. Engineered lentiviruses bearing αCD20 and SINmu wereadministered through the tail vein 6 hours after human cell transfer.After 2 days, whole blood from these mice was collected and the cellswere analyzed for surface antigens and GFP expression.

Approximately 30-40% of the cells recovered from the mice were human Tcells (CD3^(±)) and 0.1-0.3% were CD20⁺ human B cells. Three populationswere analyzed for GFP expression: CD20^(±), CD3⁺, and CD20⁻CD3⁻. None ofthe cells harvested from mice injected with virus bearing a controlantibody and SINmu (FUGW/b12+SINmu) showed evidence of GFP expression inany of the three populations (FIG. 6C). In contrast, GFP expression wasobserved in at least 40% of the CD20⁺ cells isolated from mice injectedwith FUGW/αCD20+SINmu while no transduction was detected in the othertwo populations.

This demonstration of targeting efficient gene delivery vehiclesstrictly to the desired cell types in vivo allows forlentivirus-mediated gene therapy and alleviates concerns of off-targeteffects. Possibly the most important implication of the work is thatgene therapy can now be carried out as an inexpensive procedure, andthus a viable consideration even in the less-developed world.

Example 6 Infection of Dendritic Cells Expressing the DEC-205 Receptorby Recombinant Lentiviral Vector FUGW/αmDEC-205+SINmu

To evaluate the use of affinity molecules such as surface antibodies totarget lentiviral vectors, membrane-bound antibody against the mouseDEC-205 receptor (designated as αmDEC-205) was prepared as describedabove for the anti-CD20 antibody. αmDEC-205 is an endocytic receptorabundantly expressed on dendritic cells (DCs).

A protocol was adopted to generate mouse DCs from progenitors grown inbone marrow cultures (Yang L and Baltimore D. Proc. Natl. Acad. Sci. USA102:4518 (2005)). Bone marrow cells were harvested from mice andcultured in vitro in the presence of granulocyte-macrophage colonystimulating factor (GM-CSF). On day 10 cells were collected and it wasconfirmed that 70% of the cells expressed DEC-205. Virus-cell bindingassay showed that recombinant FUGW/αmDEC-205+SINmu could bind to DEC-205positive cells. When the DCs complexed with viruses were analyzed,significant downregulation of DEC-205 was observed. Infection of thesecells with viral supernatants followed a very similar pattern to thatseen previously with αCD-20. When DCs were gated on (mCD11c high),FUGW/αmDEC-205+SINmu exhibited high infection efficiency (42%) whereasFUGW/αmDEC-205 and FUGW/SINmu exhibited virtually no infection. (SeeFIGS. 8 and 9) Downregulation of DEC-205 was observed on DCs infectedwith viruses bearing αmDEC-205. These results also showed thatrecombinant retroviruses such as described above can efficiently infectprimary cells.

Example 7 Use of a Single Chain Membrane-Bound Antibody (Anti-CD 20)with a Recombinant Lentivirus to Target CD20-Expressing Cells

A single chain membrane-bound form of antibody (scAbm) was developed asan affinity molecule target recombinant lentivirus. scAbms are typicallydesigned to have heavy chain and light chain variable domains linked bya flexible peptide linker. They also carry a signal peptide at their Nterminus and a transmembrane domain at their C terminus for anchoring tothe cell surface. A slightly different version of scAbm devised isdesignated as scaCD20. (See FIG. 10a ) This scAbm was composed of heavychain and light chain variable domains of anti-CD20 antibody linked by(GGGGSGGGS)2 (SEQ ID NO. 1) peptide, and a dimerization region includingthe hinge CH2-CH3 domain of human IgG1, and the transmembrane domain andthe cytoplasmic tail of the human HLA-A2 to display this chimericprotein on the cell surface.

The ability of scαCD20 to be expressed on the cell surface was examinedby FACS analysis. As shown in FIG. 10b , transfection of 293T cells withthe expression vector of pscαCD20 resulted in higher levels of surfaceantibody expression, when compared to those versions of scAbms without adimerization domain in the literature (e.g., de Ines, C. et al. J.Immunol. 163, 3948-3956 (1999)). This may be partially due to theinclusion of the disulfide-linked dimerization domain, which improvesstability of scAbm on the surface.

Virus-cell binding assay was employed to examine whether pscαCD20retained its binding activity. The supernatant of scαCD20-bearinglentiviruses (designated as FUGW/scαCD20+SINmu) was incubated with293T/CD20 cells and the resulting virus-cell complexes were analyzed byFACS. It was found that FUGW/scαCD20+SINmu viruses were able to bind toCD20-expressing 293T cells, indicating that scαCD20 on the viral surfacewas active.

The ability of FUGW/scαCD20+SINmu to specifically transduce CD20⁺ cellswas next investigated. As shown in FIG. 11, lentiviruses carryingscαCD20 can transduce 293T/CD20 cells expressing CD20. The titer wasestimated to be around 5×10⁵ IU/mL. Lentiviruses incorporating a singlechain antibody had a somewhat lower titer than those incorporating thenatural form of antibody, possibly because of the ability of the naturalform of the antibody to induce endocytosis. Nevertheless, these resultsdemonstrated that scAbm can be used to generate lentiviruses capable oftransducing cells expressing cognate receptors.

Example 8 Specific Infection of Cells Expressing Surface-Bound Anti-CD20Antibodies Using an Engineered Recombinant Lentivirus Carrying CD20 andFusion Proteins

Experiments to address (1) whether surface proteins other thanantibodies can be used to target lentiviral vectors, and (2) whethersurface receptors other than CD20 could be targeted for cell-specifictransduction were performed.

The use of CD20 to target cells expressing αCD20 was investigated.Unlike CD20, which is a 4-transmembrane protein, membrane-bound IgG₁ hasa C-terminal transmembrane and cytoplasmic portions that anchor themolecule in the plasma membrane. Physiologically the cytoplasmic domainscan mediate internalization of antigen-immunoglobulin complexes(Nussenzweig, M. C. Curr. Biol. 7, R355-357 (1997)). 293T cells werestably generated expressing membrane-bound αCD20, designated herein as293T/αCD20. Harnessing the nature of the budding mechanism, recombinantlentiviruses carrying CD20 and HAmu/SINmu (designated as FUGW/CD20+HAmuand FUGW/CD20+S1Nmu, respectively) were prepared. Infectivity oflentiviruses bearing CD20 was measured by transducing 293T/αCD20 andquantifying GFP expression. As shown in FIG. 12, FUGW/CD20+HAmu viruscan specifically transduce 293T cells expressing αCD20. The titer wasestimated to be about 1.2×10⁶ IU/mL. This data indicates that themembrane-bound antibody can act as a viral receptor to mediate entry oflentiviruses carrying the cognate antigen.

Therefore, it was demonstrated that transmembrane proteins such as CD20can be incorporated into the viral surface to target the lentiviralvectors, expanding the pool of proteins that can be exploited fortargeting strategies. These results also show to one of ordinary skillin the art that many different types of cell surface receptors can beutilized as affinity molecules to mediate the targeted entry.

Example 9 Specific Infection of Cells Expressing c-Kit Using anEngineered Recombinant Lentivirus Co-Displaying the Membrane-Bound Formof Stem Cell Factor (SCF) and Fusion Proteins

It was investigated whether other surface receptor-ligand interactionscould be exploited to achieve targeting. Stem cell factor (SCF)interacts with c-kit, a protein tyrosine kinase receptor on cellsurfaces, to modulate hemopoiesis. (Shimizu, Y. J. et al. J Immunol.156, 3443-34491996)). It was found that engagement of SCF with c-kit ledto rapid internalization of c-kit via the endosomal pathway (Jahn, T. etal. Oncogene 21, 4508-4520 (2002)). Casimir et al. showed thatmembrane-bound human SCF could be incorporated into ecotropicretroviruses and found that the resulting viruses were able tospecifically transduce c-kit-expressing human cells (Chandrashekran, A.,et al. Blood 104, 2697-2703 (2004)). Original ecotropic viruses do notinfect human cells because the envelope protein Eco cannot recognizemCAT expressed on the human cell surface (the mCAT derived from rodentcells is the viral receptor for Eco; Coffin, J. M. et al. (1997).Retroviruses (New York, Cold Spring Harbor Laboratory Press)). Theability of HAmu and SINmu to coordinate with SCF to target recombinantlentiviruses and retroviruses was evaluated.

The membrane-bound form of human SCF (designated as hSCF) was clonedfrom the s1/s14 hSCF220 stromal cell line (obtained from ATCC). Toconstruct the membrane-bound form of mouse SCF (designated as mSCF), thecDNA for secreted mouse SCF was linked with the transmembrane portion ofhSCF. It was found that both hSCF and mSCF could be stably displayed onthe surface of lentiviruses. When HAmu and hSCF were engineered intorecombinant lentiviruses (FUGW/hSCF+HAmu), the viruses, failed to infectTF-la cells expressing human c-kit. Similarly, FUGW/mSCF+HAmu could notinfect D9 cells expressing mouse SCF receptor. On the other hand, whenSINmu was used, FUGW/mSCF+S1Nmu and FUGW/mSCF+SINmu were able tospecifically infect c-kit positive cells TF-la and D9 respectively. (SeeFIGS. 15a and b ) Their titers were estimated to be about 1.5×10⁶ IU/mLand 4×10⁶ IU/ml, respectively. These results indicate the appropriatecoordination between fusion and recognition protein is an importantfactor for the recombinant virus to be infectious.

When retroviruses displaying mSCF and SINmu were displayed to infect D9cells, extremely high infectivity (93%) was obtained. (See FIG. 16)Retroviruses carrying only mSCF or SINmu exhibited virtually noinfection of D9 cells. The infectivity was as high as what Ecopseudotyped viruses could achieve. This indicates that receptor ligandpairs can be used to target retroviruses to particular target cells.

What is claimed is:
 1. A method of delivering a polynucleotide to a Bcell, the method comprising: infecting the B cell with a recombinantlentivirus, wherein the recombinant lentivirus comprises: (i) thepolynucleotide wherein the polynucleotide is operably linked to anexpression control sequence, and wherein the polynucleotide furthercomprises an R sequence and an U5 sequence from a 5′ lentiviral longterminal repeat (LTR), and a self-inactivating lentiviral 3′ LTR, and(ii) a viral envelope comprising a fusogenic molecule which is SINmu,and a cell-specific binding determinant which is an anti-CD20 antibodythat (a) targets the B cells, (b) is separate from the fusogenicmolecule, and (c) is incorporated into the envelope of the recombinantlentivirus.
 2. The method of claim 1, wherein the antibody comprises thelight and the heavy constant chain regions of human IgG1.
 3. The methodof claim 1, wherein the antibody further comprises immunoglobulin alphaand immunoglobulin beta.
 4. The method of claim 1, wherein the antibodyis a single chain antibody.
 5. The method of claim 4, wherein the singlechain antibody is fused with a transmembrane domain from anotherprotein.
 6. The method of claim 1, wherein the 5′ LTR and the 3′ LTR arefrom HIV.
 7. The method of claim 1 wherein the self-inactivating 3′ LTRcomprises a U3 element with a deletion of its enhancer sequence.
 8. Themethod of claim 7, wherein the self-inactivating 3′ LTR is a modifiedHIV 3′ LTR.
 9. The method of claim 1, wherein the recombinant lentivirusfurther comprises a stimulatory molecule.